附件2.1

合併與重組協議和計劃

其中：

糖基仿生物,公司

雙子座 合併子公司。;

雙子座 Merger Sub II，LLC並且

新�式生�技有限公�

日期爲2024年10月28日

目錄

展品:

合併與重組協議和計劃

本合併和重組協議計劃 （本「協議」協議日期爲2024年10月28日簽署並生效，參與方包括 GlycoMimetics公司這是一家特拉華州公司（「該公司」），母公司。 ”), Gemini Merger Sub corp公司，Parent的全資子公司，總部位於特拉華州第一合併公司”), Gemini Merger Sub II，有限責任公司，Parent的全資子公司，位於特拉華州的有限責任公司第二合併公司”及第一合併子公司，一同Merger Subs Crescent生物製藥公司，一家特拉華州公司（以下簡稱“公司”）。本協議中使用的某些大寫字母定義在 第一部分.

陳述事項

A. 父母公司打算通過本協議和DGCL的規定使第一合併子公司與公司進行合併。第一次合併完成後，第一合併子公司將不復存在，而公司將成爲母公司的全資子公司。第一次合併在本協議和DGCL的規定下，父母公司打算執行第一合併，使第一合併子公司與公司合併。完成第一次合併後，第一合併子公司將停止存在，公司將成爲父母公司的全資子公司。

在首次合併後立即，並作爲與首次合併相同的整體交易的一部分，公司將與第二次合併子公司合併（稱爲“第二次合併”和First Merger一起，構成“合併”），第二次合併子公司將成爲第二次合併的存續實體。

各方意圖，（i）第一次合併和第二次合併，合併在一起構成了《稅收法規第2001-46號》所描述的一個整體交易，符合《法典第368(a)條》中「重組」的定義，以及（ii）本協議將構成並且特此被採納爲一個重組計劃，符合財政部法規第1.368-2(g)條和1.368-3(a)條的定義。

董事會已經（i）確定擬議交易對於上級公司及其股東是公平的、明智的，並符合最佳利益，（ii）贊同並認爲本協議和擬議交易是明智的，包括根據本協議向公司股東發行上級公司股份的條款，（iii）決定根據本協議規定的條款，建議上級公司股東投票批准本協議，從而批准上級公司股東事項，包括擬議交易，並反對任何競爭提案。

第一併購子公司董事會已經（i）確定擬議的交易對第一併購子公司及其唯一股東是公平的、明智的並且符合最佳利益，（ii）批准並宣佈本協議和擬議的交易是明智的，（iii）決定推薦，根據本協議規定的條款和條件，要求第一併購子公司的股東投票通過本協議，並因此批准擬議的交易。

第二次合併子公司唯一成員已確定擬議交易對第二次合併子公司及其唯一成員公平、明智且符合最佳利益，已批准並宣佈本協議和擬議交易明智，已決定根據本協議中規定的條款和條件推薦第二次合併子公司的唯一成員投票通過本協議，並因此批准擬議交易。

G. 公司董事會已確定擬議交易對公司及其股東是公平合理且符合最佳利益，已批准並認爲本協議及擬議交易是合理的，已決定根據本協議載明的條款和條件向公司股東推薦，要求他們投票通過本協議，並因此批准擬議交易。

同時與本協議的執行和交付一起，並作爲公司願意進入本協議的條件和誘因之一，列名在 A部分 的母公司披露函中（僅以母公司股東身份）簽署支持協議，形式基本如附件所示的 附件A-1 (「本登記聲明」) 由特立軟件股份有限公司，一家德拉華州股份公司 (以下簡稱爲「本公司」) 提交，目的是爲了註冊其額外的7,184,563股A類普通股，每股面值$0.0001 (以下簡稱爲「A類普通股」), 以及在特立軟件股份有限公司 2022年股權激勵計劃下可發行股份的1,436,911股A類普通股，注(下文簡稱爲「A類普通股」)。母公司股東支持協議，根據其中規定的條款和條件，這些人同意投票支持母公司股份的全部股份，以贊成本協議的批准並批准擬議的交易，如果母公司認爲有必要，還可以修正母公司的公司章程以實施納斯達克的逆向分拆和其他事項，並反對任何競爭性提案。

I. 同時 本協議的執行和交付，並作爲父母願意簽訂本協議的條件和激勵 協議，本公司的每位高級職員、董事和股東在上市 A部分 公司披露信息 信函（僅以公司股東的身份）正在執行實質上有利於母公司的支持協議 此處所附的表格爲 附錄 A-2 （這個”公司股東支持協議”），據此 在遵守其中規定的條款和條件的前提下，這些人已同意對其所有公司股本進行投票 贊成通過本協議，從而批准預期的交易，反對任何競爭提案。

在簽署並交付本協議的同時，作爲控件並誘因，公司或母公司有意進入本協議的所有股東列名 B板塊 公司披露函的第一部分的附表所附的基本形式的鎖定協議 展B (「本登記聲明」) 由特立軟件股份有限公司，一家德拉華州股份公司 (以下簡稱爲「本公司」) 提交，目的是爲了註冊其額外的7,184,563股A類普通股，每股面值$0.0001 (以下簡稱爲「A類普通股」), 以及在特立軟件股份有限公司 2022年股權激勵計劃下可發行股份的1,436,911股A類普通股，注(下文簡稱爲「A類普通股」)。鎖定協議，「協議」中指的是本修訂協議。鎖定協議”).

預計在此後的兩個（2）個工作日內，持有足夠公司股本股份的股東將簽署並批准本協議和合並，如DGCL及公司章程和公司規則所要求，以書面同意書的形式執行和交付，以獲得必要的公司股東表決。

同時與本協議的簽署和交付，某些投資者已根據附件中附有的證券購買協議執行了協議 附件C。在本第2(e)規定適用的範圍內，確定本認購證證券是否可行使（與持有人及其關聯方及歸屬方擁有的其他證券有關）以及本認購證證券的哪部分可行使，包括髮行交換認購證證券來代替認購證證券，應完全由持有人自行決定，並且行使通知書應視爲持有人確定本認購證證券是否可行使（與持有人及其關聯方及歸屬方擁有的其他證券有關），以及哪部分可行使，但仍應受到持有限制的約束，公司無需驗證或確認此種決定的準確性。 父公司和其中列名的人之間（包括可能根據時間不斷改編、重新規定和/或取代的人）之間的認購協議），根據該協議，這些人同意購買父公司普通股和預先擬定的權證，以購買父公司普通股，第二有效日期之後的金額，即“母公司融資”).

協議

各方有意具有法律約束力，同意如下：

第1節。定義和解釋條款。

1.1          定義.

(a)根據本協議的目的（包括本第1節）：

“可接受的保密協議「」指包含的保密協議，其條款在總體上與交易對方的保密協議條款不具有實質性較少的限制，除非該保密協議不得包括任何停滯、禁止招攬或不得僱用條款。儘管前述規定，曾與母公司就潛在收購提議簽訂過在涵蓋範圍和披露和使用限制方面與保密協議相比不具有實質性較少限制的條款的個人，無需簽訂新的或修訂後的保密協議，並且應視現有保密協議爲可接受的保密協議。

“收購詢問” 表示就一方而言，指詢問、興趣表達或請求非公開信息（不包括公司一方或母公司另一方向另一方提出的詢問、興趣表達或信息請求），該詢問、興趣表達或信息請求可以合理預計可能導致收購提議。

“收購提案對於某一方，""表示任何出價或提議，無論是書面還是口頭的（不包括由公司或其關聯公司代表或提交的出價或提議，一方面或由父公司或其關聯公司代表或提交的出價或提議另一方面，與另一方有關或與該方進行任何收購交易。

“收購交易“ 表示任何交易或一系列相關交易（除了任何中期融資、任何公司收購或母公司融資）涉及：

(a) 任何合併、合併、合併、股份交換、業務組合、證券發行、證券收購、重組、資本重組、要約收購、交換要約或其他類似交易：(i) 在此交易中，直接或間接收購任何一方或其任何附屬公司任何一類有表決權證券的證券所代表的超過該方或其任何附屬公司已發行證券中超過20％的權益或股份; (ii) 在此交易中，任何一方或其任何附屬公司發行的證券代表該方或其任何附屬公司已發行證券中超過20％的任何一類有表決權證券的權益，或發行的證券可轉換爲該方或其任何附屬公司已發行證券中超過20％的任何一類有表決權證券的權益;

(b) 任何業務或資產出售、租賃、交換、轉讓、許可、收購或處置，構成一方及其子公司資產的合併賬面價值或公允市場價值的20％或更多，作爲整體。

“附屬公司“ 在《證券法》第145條下賦予該術語的含義。

“經濟實惠醫療法案 ” 意味着患者保護和經濟實惠醫療法案。

“預期截止日期 ”代表雙方父公司和公司商定的預期截止日期。

“第十章 轉讓證券 第10.1節 交易 如果發行受託人證明，債券持有人可以交換並迅速交付發行受託人這樣的證明，無論是有欠款未償還，還是實質性週轉的時候，都可以在世界範圍範圍內經由源和債券市場交易。” 表示任何紐約州銀行有權或有義務關閉的非工作日。

“指定證書「」 意味着母公司可轉換優先股的偏好、權利和限制指定證書 所附的表格如下所示 附件 E.

“ 「COBRA」是1985年頒佈的《綜合預算協調法案》，載於法典第49800億節和ERISA第I標題第6節。

“代碼「」指1986年修訂版的國內收入法規。

“公司關聯人員” 指公司或其任何子公司的任何在職員工、獨立承包商、高管或董事。

“公司董事會「董事會」是指公司的董事會。

“公司資本 股票”指公司普通股和公司優先股。

“公司資本化 陳述”表示公司在《 第3.6(a)節和 第3.6(d)節.

“公司普通股” 表示每股面值爲$0.0001的公司普通股。

“公司合同“ 意味着任何合同：(a) 公司或其任何子公司是一方的合同，(b) 公司或其任何子公司是或可能成爲約束方或者在公司或其子公司履行任何義務或可能成爲受約束方的合同，或者(c) 公司或其任何子公司在其中具有或可能獲得任何權利或利益的合同。

“公司員工計劃”指的是公司或其任何子公司（i）贊助、維護、管理或貢獻的任何員工計劃，（ii）可以合理預期承擔任何責任的計劃，或（iii）用於爲公司或其任何子公司（或其配偶、受撫養人或受益人）的當前或前任僱員、官員、董事或其他服務提供者提供福利或覆蓋風險，但不包括公司或其任何子公司參與的由任何專業僱主組織贊助的任何員工計劃。

“公司基本 陳述”表示公司在《 章節 ‎3.1(a), ‎3.2, ‎3.3, ‎3.4, ‎3.5(a)(i) 和 ‎3.20.

“ ” 指由公司或其子公司擁有、被聲稱擁有、被分配、被獨家許可或被控制的所有知識產權權利，這些知識產權權利對於公司及其子公司目前開展業務所必需，或用於業務運營，或用於業務運營。

“公司知識產權協議「」指任何管理、涉及或與公司知識產權有關的合同，但不包括根據保密協議提供的任何機密信息。

“公司重要員工“ 意味着公司的任何執行官或其任何子公司的任何執行官。

“公司材料 不利影響「公司重大不利影響」指任何效應，結合發生在確定之日前的所有其他效應，對公司或其子公司的業務、財務狀況、資產、負債或業務結果作爲一個整體產生或合理預期將產生重大不利影響； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。對於決定是否發生公司重大不利影響，不應考慮以下效應：(a)本協議的公告或擬議交易的進行狀態，(b)公司採取或未採取爲遵守本協議條款而必須採取的任何行動，(c)任何自然災害、災害或流行病、大流行病或其他不可抗力事件，或任何恐怖主義或戰爭的行爲或威脅，任何全球任何地方的武裝衝突或恐怖主義活動(包括上述任何事件的升級或普遍惡化)，以及對上述任何事件的任何政府或其他響應或反應，(d)GAAP或適用法律或其解釋的任何變化，(e)普通經濟或政治狀況或普遍影響公司及其子公司所在行業的條件或(f)由於在業務的正常經營過程中產生的公司及其子公司的現金頭寸變化；除了在(c)、(d)和(e)各項，相對於公司及其子公司相對於在公司及其子公司所在行業中處於類似境遇的其它公司所產生的影響有明顯不成正比之處，作爲整體考慮。

“公司合併 股份”表示由確定的產品 乘以 （i）發帖收盤後的母公司股份數 （ii）公司分配比例，其中： 除（i）發帖收盤後的母公司股份數 （ii）公司分配比例，其中：

“公司備忘錄「」指的是公司於2024年10月24日前後發行的可轉換票據，包括其中規定的第二筆款項。

“公司期權” 表示購買公司發行的公司股票的期權或其他購買權。

“首選股「」代表公司資本股中指定爲優先股的股份，包括公司種子優先股。

“公司註冊 知識產權「公司註冊」表示公司所有或獨家許可的公司知識產權，經政府機關授權、審批或頒發的註冊、備案或發行，包括所有專利、註冊版權和註冊商標以及所有前述任何內容的申請和註冊。

“公司系列種子 優先股”表示公司指定爲「種子優先股」的一系列首選股，每股面值爲$0.0001。

“公司股票計劃“ 意味着公司的2024年股權激勵計劃。

“公司觸發事件如果在本協議通過並獲得所需公司股東投票批准之前的任何時候發生以下情況，則應視爲已發生：“公司董事會已做出公司董事會不利建議更改；(b) 公司董事會或其任何委員會已公開批准、支持或推薦任何收購提議；或(c) 公司已簽署任何意向書或類似文件或與任何收購提議相關的任何合同。

“公司認股權證“ 意指公司發行的可購買公司股票的認股權證。

“保密協議「」指的是2024年9月17日公司與母公司之間簽訂的信函協議。

“同意“ 表示任何批准、同意、批准、許可、放棄或授權（包括任何政府授權）。

“擬議的交易” 表示本協議所 contempl.Point 和其他交易（除了母公司憲章修正案外），母公司融資和納斯達克逆向拆分（在適用和母公司及公司認爲必要的範圍內）。

“合同「對於任何個人而言，」通常指的是任何書面協議、合同、分包合同、租賃協議（無論是用於不動產還是動產）、抵押貸款、許可證或其他根據適用法律對其構成約束或影響的具有法律約束力的承諾或行爲。

“特拉華州公司法「」是特拉華州公司法。

“DLLCA” 意指特拉華有限責任公司法。

“投票「棄權」的效果“ 意味着任何影響、變化、事件、情況或發展。

“員工計劃"意味着（A）根據ERISA第3(3)條的「員工福利計劃」，無論是否受ERISA約束；（B）其他計劃、項目、政策或安排，提供股票期權、股票購買、基於股權的薪酬、獎金（包括任何年度獎金和保留獎金）或其他激勵、離職費、延期薪酬、僱傭、薪酬、交易變更獎金、補充、休假、退休福利（包括退休後的醫療福利）、養老金福利、利潤分享福利、邊際福利、人身保險福利、津貼、健康福利、醫療福利、牙科福利、視力福利以及所有其他員工福利計劃、協議和安排，不屬於（A）以上；和（C）提供報酬給員工、顧問和非僱員董事的所有其他計劃、項目、政策或安排。

“負擔「質押」的含義是任何抵押、質押、抵押、抵押、擔保權益、租賃權、獨家許可、選擇權、權力、預留、 服務權、不動產權益、權利、侵權、干涉、選擇權、優先購買權、社區財產權益或限制或任何性質的負擔（包括對任何 證券的投票限制、對任何證券或其他資產的轉讓限制、對任何資產所得收入的收取限制、對任何資產使用的限制以 及對任何其他資產所有權屬性的佔有、行使或轉讓的任何限制）。

“可執行性例外 「」表示（a）有關破產、清償債務及債務人救濟的普遍適用法律和 （b）規定具體履行、禁止令和其他衡平救濟的法律規則。

“實體“ 意味着任何公司（包括任何非營利公司）、合夥企業（包括任何普通合夥、有限合夥或有限責任合夥）、合資企業、遺產、信託、公司（包括任何有限公司、有限責任公司或股份有限公司）、公司、協會或其他企業、協會、組織或實體，以及其各自的繼承人。

“環境法” 指任何與污染或保護盈健醫療或環保母基（包括環境空氣、地表水、地下水、地表或地下地層）有關的聯邦、州、地方或外國法律，包括任何與危險物質的排放、排放、釋放或受威脅的釋放，或與危險物質的製造、加工、分銷、使用、處理、儲存、處置、運輸或處理有關的法律或法規。

“ERISA會員公司對於任何實體，"其他" 意味着任何被視爲與該實體構成單一僱主或在法規414(b)、(c)、(m) 或 (o) 下被視爲同一"受控組" 的其他人。

“ERISA 「ERISA」的意思是1974年修訂的僱員退休收入安全法案。

“使擁有公司註冊證券類別10%以上股權的官員、董事或實際股東代表簽署人遞交表格3、4和5（包括修正版及有關聯合遞交協議）,符合證券交易法案第16(a)條及其下屬規則規定的要求；表示1934年修訂版的證券交易法。

“第一併購子公司 董事會” 意指第一併購子公司的董事會。

“政府機構“ 意味着任何：(a) 國家、州、聯邦、地區、縣、市、區或其他性質的司法管轄區， (b) 聯邦、州、地方、市政、外國、超國家或其他政府，(c) 任何性質的政府或準政府權力 (包括任何政府部門、部門、機構、委員會、局、機構、官員、部、基金、 基金會、中心、組織、單位、主體或實體和任何法院或其他法庭，爲避免疑問， 任何徵稅權威) or (d) 自律組織(包括納斯達克)。

“政府授權“ 代表任何：（a）由任何政府機構授權或根據任何法律頒發、授予、證書、特許經營權、許可證、特許證、權限、變數、豁免、訂單、批准、許可、清關、註冊、資格或授權，或以其他方式由其發放、授予、給予或提供; 或（b）根據與任何政府機構訂立的任何合同中的權利。

“危險物質” 意指任何受環保母基管制、控制或整治的污染物、化學物質和任何具有毒性、傳染性、致癌性、活性、腐蝕性、易燃或可燃性的化學物質，或化合物，或危險物質、物料或廢物，無論是固體、液體還是燃料幣，包括但不限於原油或其任何餾分，以及石油股產品或副產品。

“HSR法案“ 代表1976年修訂後的美國哈特-斯科特-羅迪諾反壟斷改進法案。

“已實現盈利期權”表示行權價等於或低於母公司收盤價的母公司期權。

“知識產權“ 表示：(a)美國、外國和國際專利，專利申請，包括所有臨時，非臨時，替換，分部，延續，部分延續，再發行，延伸，補充保護證書，複審，期限延長，發明證書及前述任何等效物，法定發明註冊，發明披露和發明（統稱爲「所有板塊」，(b)商標，服務標記，商號，域名，公司名稱，品牌名稱，URL，商業裝潢，標誌和其他來源標識，包括註冊和註冊申請及相關的商譽，(c)版權，包括其註冊和註冊申請，(d)軟件，包括所有源代碼，目標代碼和相關文檔，(e)公式，客戶列表，商業祕密，技術訣竅，機密信息和其他專有權利和知識產權，無論是否可以獲得專利，以及與前述任何事項相關的所有美國和外國權利。專利”），(b)商標，服務標記，商號，域名，公司名稱，品牌名稱，URL，商業裝潢，標誌和其他來源標識，包括註冊和其註冊申請及相關商譽，(c)版權，包括其註冊和註冊申請，(d)軟件，包括所有源代碼，目標代碼和相關文檔，(e)公式，客戶列表，商業祕密，專有技術，機密信息和其他專有權利和知識產權，無論是否可以獲得專利，及(f)所有與上述任何事項相關的所有美國和外國權利。

“臨時融資“ 指公司自本文件日期後完成的任何普通股或優先股（視情況而定）的銷售（或一系列相關銷售）； 不過 公司票據的發行和母公司融資不構成臨時融資.

“美國國家稅務局（「IRS」）” 表示美國國內稅務局。

“知識” 表示，（i）對於個人，指個人實際知曉相關事實或該個人在履行就業職責的日常工作過程中應該合理地知曉該事實；（ii）對於作爲實體的任何人，自該知識被推定的日期以來，該人的任何執行官都有知識。 對於知識產權相關事項，此意識或合理預期知曉的要求並不需要任何個人進行或已經進行或獲得或已獲得律師意見的自由操作意見或任何知識產權清理搜索。

“法律” 表示任何政府機構（包括納斯達克或金融行業法規機構）的權威發佈、頒佈、採納、頒佈、實施或由其授權發佈、頒佈、採納、頒佈、規定、條例、法令、法規、裁決或要求的任何聯邦、州、國家、超國家、外國、地方或市政法律、法令、憲法、普通法原則、決議、法令、法典、敕令、規則、規定、裁決或規定。

“法律訴訟” 意味着任何由法院或其他政府機構或任何仲裁員或仲裁小組啓動、提起、進行或聽取的任何訴訟、仲裁、訴訟、仲裁、程序（包括任何民事、刑事、行政、調查或上訴 程序）、聽證會、調查、審計、檢查或調查。

“最低同時投資金額”表示（i）$100,000,000 減去 （ii）交易完成前與公司有關的任何中期融資實際收到的款項金額。

“多僱主計劃 ” 表示《僱主退休收入安全法》第3(37)或4001(a)(3)節中定義的「多僱主計劃」。

“多僱主計劃”表示《稅收法》第413(c)條或《僱員退休保障法》第3(40)條所述的「多僱主計劃」。

“多僱主 福利安排”表示根據ERISA第3(40)條規定的「多僱主福利安排」

“納斯達克逆向拆股「」代表父公司爲了符合納斯達克上市標準而進行的所有流通普通股的逆向拆分。

“納斯達克資本市場”代表納斯達克股票市場。

“命令“ 意味着任何判決、命令、書面命令、禁令、裁定、決定或法令（適用於一方）；或者任何關於任何法院或政府機構的辯訴協議、企業廉正協議、解決協議或延期起訴協議，或在其管轄範圍內達成的任何和解協議。

“業務的常規操作“在公司和母公司的情況下，指的是按照其業務的常規操作，並與其過去的慣例一致，或者對於公司而言，按照類似發展階段最近成立公司的慣例操作。

“組織文件對於任何人（除個人外），"收據" 意指： （a）該人員的證書或章程或組織或有限合夥或有限責任公司，以及任何合資企業、有限責任公司、運營或合夥協議以及在創建、組建或設立該人員時採用或提交的其他類似文件； （b）所有章程、規章和類似文件或協議，涉及該人員的組織或治理，均作爲修訂或補充。

“虛值 基礎期權「」表示行權價高於母公司收盤價格的母公司期權。

“家長關聯人” 指Parent或其任何子公司的任何現任僱員、獨立承包商、高管或董事。

“母公司資產負債表”表示截至2023年12月31日的母公司經審計的資產負債表，包括在母公司提交給美國證券交易委員會的截至2023年12月31日的年度報告Form 10-K中。

“母公司董事會” 代表母公司的董事會。

“母公司股本 股票” 意味着母公司普通股和母公司優先股。

“母公司資本化 陳述”表示母公司和合並子公司在 第4.6(a)節和 第4.6(d)節.

“母公司收盤價格「」指的是納斯達克上母公司普通股五（5）個相繼交易日收盤前三（3）個交易日的成交量加權平均收盤交易價格，由彭博社報告。

“母公司普通股” 指的是母公司的普通股，每股面值爲$0.001。

“母公司合同“ 意指任何合同： (a) 其中父母是一方， (b) 使父母或任何父母IP權利或父母的任何其他資產 受拘束或可能受拘束或受任何義務或公司（c）公司或可能受拘束公司獲得任何權利或利益。

“母公司可轉換優先股「」表示母公司的非表決可轉換優先股，每股面值爲$0.001，具有在指定的指定書中規定的權利、偏好、權力和特權。

“母公司員工計劃”表示母公司或其任何子公司（i）贊助、維護、管理或投入資金的任何員工計劃，（ii）可以合理地預期產生任何責任，或（iii）用於爲母公司或其任何子公司（或其配偶、受撫養者或受益人）的現任或前任員工、官員、董事或其他服務提供者提供福利或其他保障的計劃，但不包括任何母公司或其任何子公司參加的、由任何專業僱主組織贊助的員工計劃。

“家長 基本表現”表示母公司和合並子公司在 第4.1(a)節, ‎4.2, ‎4.3, ‎4.4, 4.5(a)(i) 和 ‎4.21.

“父母知識產權協議 協議”表示任何管理、關聯或涉及父母知識產權的合同。

“「Parent IP Rights」指的是父公司擁有、許可或控制的所有知識產權，這些知識產權對父公司的業務的運營是必要的、被使用或保留以供使用。“means 父公司擁有、許可或控制的所有知識產權，其中必要的知識產權，或用於經營父公司業務的知識產權或爲此而持有的知識產權。

“父公司關鍵員工” 指（i）母公司的執行官員；和（ii）直接向母公司董事會或母公司執行官彙報的任何母公司僱員。

“原材料 不利影響「所述」表示任何效果，將與發生在確定母公司重大資產負面影響發生日期之前的所有其他效果一起考慮，已經或理應對母公司及其子公司的業務、財務狀況、資產、負債或經營業績作出實質上不利的影響； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。以下效果產生的父母公司重大資產不良影響不應納入檢驗範圍：(a) 本協議的公告或擬議交易的懸而未決， (b) 母公司普通股的股價或交易量的任何變化（但應理解的是，任何導致母公司普通股股價或交易量變化的效果可在決定母公司重大資產不良影響是否已經發生時計算在內，除非這些效果在本定義範圍之外），(c) 母公司採取或未能採取的任何行動，以便遵守本協議條款，(d) 任何自然災害、災禍、流行病、大流行病或其他不可抗力事件，或全球任何地方的恐怖主義或戰爭行爲、任何武裝衝突或恐怖主義活動（包括任何上述行爲的升級或普遍惡化），或任何政府或其他機構對上述任何行爲的回應或反應，(e) 對公司會計原則或適用法律或其解釋的任何變化，(f) 一般經濟或政治條件，或一般影響母公司或其子公司所處行業的條件，(g) 未能達到或維持母公司淨現金的任何最低水平，(h) 證券交易委員會關於母公司根據交易所法案的報告狀態的任何決定，或 (i) 源自母公司 Uproleselan (GMI-1271) 項目的臨床前試驗、臨床試驗和/或測試的結果、結論、數據、指標、不利事件、副作用或安全觀察，包括進行進一步臨床研究或測試的任何要求或任何先前確認的副作用、不良事件、臨床觀察或報告發生的副作用、不良事件、安全觀察的發生率或嚴重程度增加或有關任何新副作用、不良事件或安全觀察的公開聲明；除了，在情況(d)、(e) 和(f)下，如果相對於母公司或其子公司的整體狀況影響程度顯著且不成比例於母公司或其子公司所處行業中其他類似公司，則不考慮。儘管如上，母公司普通股在納斯達克上市下市將構成母公司重大資產不良影響，前提是公司未拒絕或不合理延遲同意母公司採取合理行動以維持母公司普通股在納斯達克的上市。

“家長淨現金” 指不重複的意思，(i) 母公司確定的無限制現金和現金等價物以及有價證券 符合公認會計原則的範圍，其方式與歷史上確定此類項目的方式一致，並符合 並在母證券交易委員會文件中包含或以引用方式納入財務報表（包括任何相關附註）以及 母公司資產負債表， 加 (ii) 上列出的所有預付費用 第 1.1 (a) 節家長披露信息 信， 減去 (iii) 母公司合併的短期和長期合同義務和負債總額 在截止日期累計，在每種情況下均根據公認會計原則確定，在符合公認會計原則的範圍內，以某種方式確定 符合歷史上確定此類項目的方式，也符合財務報表（包括 任何相關票據）包含或以引用方式納入母公司證券交易委員會文件和母公司資產負債表中， 減去 (iv) 父母在首次生效之前產生的所有費用和開支的總金額（不含重複） 與預期交易的關聯，不包括任何母公司淨現金不包括的支出，但包括（在不包括母公司的範圍內） 淨現金（不包括費用）：（a）法律顧問，會計師，財務顧問，投資銀行家，經紀人的任何費用和開支， 母公司與預期交易相關的顧問、稅務顧問和其他專業顧問；(b) 50% 向美國證券交易委員會支付的與向美國證券交易委員會提交委託書及其任何修正和補充相關的費用；(c) 50% 與印刷、郵寄和分發委託書以及任何修訂和補充相關的費用和開支 其中；(d) 納斯達克費用的50％；（e）任何獎金、留用金、遣散費、控制權變更補助金或類似款項 債務（包括在交易完成時和交易完成時觸發的 「單一觸發」 條款的付款） （特此設想）與完成相關的任何董事、高級職員、僱員或顧問的到期或應付款 預期交易的內容，以及與之相關的任何工資稅；(f) 與獲得交易相關的成本 根據的 「D&O 尾部政策」 第‎6 .7 節 在每種情況下，以第一次生效之日起未付的數額爲限 時間；以及 (g) 爲避免疑問，收盤時任何母公司淨現金不包括支出的實際金額的金額 超過了家長披露信附表1.1（b）中規定的估計， 減去 (v) 所有剩餘租金 母公司租賃義務下的付款和任何其他負債， 減去 (vi) 母公司的任何未繳稅款以及 截至截止日期或之前的納稅期（或部分納稅期）的子公司，以及 加 (vii) 300,000 美元 2025 年 6 月 30 日之後延遲收盤的每個月或其中的一部分（除非此類延遲主要是由於 根據母公司的行動），該金額應從2025年7月1日開始累計（例如，如果收盤時間推遲到（A）7月31日， 2025 年由於此類故障，母公司淨現金將增加 300,000 美元，或者 (B) 因此在 2025 年 8 月 30 日增加 失敗，則60萬美元將添加到母公司淨現金中）； 但是, 前提是, 如果所描述的費用和開支的任何部分 在第 (iv) 款 (b)、(c) 和 (d) 項中，父母已在首次生效之前以更高的金額支付了第 (iv) 款 超過父母在 (b)、(c) 和 (d) 小節中描述的此類費用和開支中所佔的份額，然後 (x) 超過該部分的金額 不得以小節爲由扣除 (b)、(c) 和 (d) 小節所述的此類費用和開支中父母應分的份額 第 (v) 和 (y) 條的 (b)、(c) 和 (d) 這些部分應添加到母公司淨現金的計算中。爲了避免 不容置疑，(i) 母公司融資中收到的現金將不計入母公司淨現金的計算；(ii) 計算母公司淨現金可能得出低於0美元的數字。

“上級公司淨現金 不包括費用「」表示母公司在首次生效日期之前因涉及 所規定的籌劃事項而發生的費用和支出 第1.1(b)節母公司披露函的第 一段將包括 對關閉之前母公司淨現金不包括費用的描述和善意估計。

“父母期權” 表示父公司授予的購買母公司普通股期權或其他購買權利，包括根據任何父公司股票計劃而授予的。

“母公司優先股”表示母公司普通股中指定爲優先股的股份，每股面值爲$0.001， 包括母公司可轉換優先股。

“註冊家長IP「」指的是所有由父公司擁有或獨家許可，在任何政府機構的授權下注冊、備案或頒發的所有家長IP權利，包括所有專利、註冊版權和註冊商標，以及所有上述權利的申請。

“父母限制性 股票單位” 表示任何與父公司普通股有關的權益獎勵，代表 未來擁有父公司普通股的權利，根據任何父公司股票計劃。

“父母觸發 事件在父母公司股東批准本協議和擬議交易之前，如果發生”，則視爲已發生 第6.3(c)節：(a) 父母未在代理聲明中包含父母董事會推薦，(b) 父母董事會或其任何委員會已作出父母董事會不利推薦變更或受第6.3(e)節限制 第6.3(e)節，公開提議、支持或推薦任何收購提案或(c) 父母與任何收購提案有關的任何意向書或類似文件或任何合同（除接受的根據第5.4節允許的可接受的保密協議之外） 第5.4節).

“方”或“當事人「」指的是公司、合併子公司和母公司。

“允許的備選方案 協議”表示具有關於構成更有利報價的收購交易的明確協議或其他相關協議。

“允許的抵押權” 意味着（a）尚未到期和應支付的當前稅收的任何法定留置權，或者正在通過適當程序進行善意爭議的稅款，且根據美國通用會計準則（GAAP）在公司財務報表或母公司資產負債表（如適用）中將會或已經做出充分準備或預留；（b）在日常業務中產生的次要非貨幣形式的留置權，不會（在任何情況下或總體上）明顯減少資產的價值或嚴重損害公司或母公司的運營；（c）用於保障債務人對房東、出租人或租賃協議項下租約或租賃協議的留置權；（d）與工傷保險、失業保險或法律規定的類似計劃有關的存款或質押；（e）爲保障運輸商、倉庫管理人員、機械師和材料供應商權利的法定留置權，保障尚未到期和應支付的勞務、材料或供應費用；以及（f）依適用證券法律規定產生的留置權。

“持有” 表示任何個人、實體或政府當局。

“個人信息「」表示任何組成「個人信息」、「個人數據」、「可識別個人信息」、「受保護健康信息」或適用法律下類似術語的任何數據或信息，包括任何此類信息識別、涉及、描述、與之關聯、能夠合理與之關聯或可能與之連接的，直接或間接地，與任何確定或可識別的個人或家庭有關。

“隱私法律” 指的是集體（i）所有管理隱私、數據保護、數據安全、跨境數據流動、數據丟失、數據盜竊、數據泄露通知、數據本地化、發送有求或無求的電子郵件或短信、Cookies或其他跟蹤技術，以及個人信息的收集、處理、使用、維護、存儲、披露、傳輸或其他處理的所有法律規範，包括監管機構發佈的具有約束力的法規和包含同意命令的協議，如美國聯邦貿易委員會、美國聯邦通信委員會或州數據保護部門發佈的HIPAA、聯邦貿易委員會法案第5節、控制非請求色情和市場法案、電話消費者保護法以及美國州消費者保護和數據泄漏通知法律，以及（ii）任何自我監管組織約束數據隱私、數據保護、數據安全、跨境數據流動、數據丟失、數據盜竊、數據泄露通知、數據本地化、發送有求或無求的電子郵件或短信、Cookies或其他跟蹤技術，以及個人信息的收集、處理、使用、維護、存儲、披露、傳輸或其他處理的任何具有法律約束力的要求，包括支付卡行業數據安全標準。

“代表” 表示對於一個人，這個人的董事、高級職員、僱員、代理人、律師、會計師、投資銀行家、顧問和其他代表。

“2002年的薩班斯-奧克斯利法「」表示2002年的薩班斯-豪利法案。

“SEC” 表示美國證券交易所。

“證券法「證券法」是1933年頒佈的《證券法》的修改版。

“後續交易” 意味着任何收購交易（在收購交易定義中所有對20%的引用被視爲對這些目的的50%的引用）。

“「財政部條例」是指根據《稅收法典》頒佈的所有擬議、臨時和最終條例，這些條例可能會不時修訂（包括後續條例的相應規定）。” 意味着，對於一個實體而言，如果這個人直接或間接擁有或據稱擁有對該實體具有足夠權利選舉至少其中大部分董事會成員的投票證券或其他權益，或者至少擁有該實體所有已發行股權、投票權、受益權或財務利益的50%以上。

“優越報價” 指的是一項未經請求的真實書面收購提議（在收購交易定義的20%中的所有參考均視爲指向50%，在這些情況下）：（a）不是直接或間接違反本協議的結果獲得或制訂；（b）所涉及的條款和條件由母公司董事會或公司董事會根據其認爲相關（包括完成可能性和融資條件等）的事項誠信確定，並對本協議的另一方提出修改本協議條款的任何書面提議進行諮詢，並在諮詢其外部法律顧問和財務顧問（如有的話）後，從財務角度看，更有利於母公司股東或公司股東的條款與思考交易條款相比，（c）不受任何融資條件的約束（如果需要融資，則該融資已完全承諾給第三方），以及（d）能夠合理地按照提議的條件完成。

“納稅申報「申報」指提交給任何政府主體（或提供給任何支付對象）的任何回報（包括任何信息回報）、報告、聲明、索賠或退款、估算、時刻表、通知、表格、選舉、證明或其他文件或信息，以及對前述任何文件的任何修訂或補充，與稅務的確定、評估、徵收或繳納以及與任何涉及稅務的法律的執行、實施或強制執行或遵守有關的法律的管理有關。

“稅務” 代表任何美國聯邦、州、地方、外國或其他稅，包括任何所得稅、特許稅、資本利得稅、毛收入稅、增值稅、附加稅、預估稅、就業稅、失業稅、國民健康保險稅、環保稅、消費稅、從價稅、轉讓稅、過戶稅、契據稅、印花稅、銷售稅、使用稅、財產稅、營業稅、代扣代繳稅、社會保障稅、關稅、執照稅、替代或附加最低稅額或其他稅或類似費用、稅務、關稅、徵費、關稅、課徵額、稅款，稅務官方徵收的罰款、處罰、稅款增加、對其徵收的利息或額外金額（或因未支付而歸屬）。

“計劃應由委員會管理，該委員會應由董事會根據情況確定的一個或多個董事組成。「美國財政部根據法典頒佈的規定。」

(b) 以下術語在相應段落中的定義如下所示：

1.2            其他 定義和解釋性規定在本協議中使用的「本協議」，「本協議中」，「本協議下」及類似含義的詞語將指代整個協議而非特定條款。 本協議中的標題僅供參考便利，不影響本協議的解釋和理解。 本協議中對「章節」、「附件」和「附表」的引用均指本協議的章節、附件和附表，除非另有規定。 任何附件或附表中使用的大寫詞彙但未在其中另行定義的，應當按照本協議中的定義解釋。本協議中任何單數詞彙均被視爲包括複數形式，任何複數詞彙均被視爲包括單數形式，男性性別包括女性和中性性別，女性性別包括男性和中性性別，中性性別包括男性和女性性別。每當本協議中使用「包括」、「包含」或「包含」的詞語時，應當被視爲後面跟隨「不限於」這幾個詞，無論實際上是否跟隨這些詞或類似含義的詞。單詞「或」的使用不具排他性。『書面』、『書面的』及類似詞指印刷、打字和其他方式以可見形式複製單詞（包括電子媒體）。對於任何協議或合同的引用（除了父公司披露信函或公司披露信函中列出的協議或合同的引用），指的是按照本協議的條款和該協議自時間至時間經過修改、修訂或補充的協議或合同。本協議的附件、父公司披露信函和公司披露信函是本協議解釋的組成部分，但只有附件 D-1（包括該附件的附件 A）和附件 D-2被引用並作爲第 251 條對 DGCL 的目的之一的一部分納入。對任何個人的引用包括其繼承人和被許可的受讓方。對任何法規的引用包括該法規及其根據該法規制定的規則和規定，均按照經過修訂、修改、重新頒佈、替換的方式進行，從時間至時間。對於「$」和「美元」的引用指的是美元貨幣。本協議中使用的所有會計術語將按照通常會計原則（GAAP）解釋，除非另有明確規定。從或通過任何日期的引用意味着除非另有規定，從該日期和包括該日期或截止於該日期和包括該日期。所有對「天」的引用均指日曆天，除非另有指示爲「工作日」。除非另有具體說明，爲了測量本協議中時間段的開始和結束（包括「工作日」和每日或工作日中的小時數計算），事件或時間的開始或結束所發生的時間將被視爲美國東部時區發生的時間。各方一致同意，不適用任何解釋規則使模糊不明確的對草擬方有利的情況，在本協議的解釋和理解中。各方同意公司披露信函或父公司披露信函將按照編號和字母標註的部分和子部分排列。 第3部分或。第4節分別。公司披露函或母公司披露函的任何部分或子部分中披露的內容應視爲對其他部分和子部分具有資格。第3部分或。第4節，在披露的閱讀中明顯可看出此類披露適用於其他部分和子部分。"交付"或"提供"一詞意味着，就任何文件而言，在本協議日期前一天下午5:00（紐約時間）之前，這樣的文件副本已（a）由一方發佈並持續向另一方及其代表提供，放置在由披露方維護的電子數據室中，用於擬議交易目的，或（b）由一方或其代表或代表的代表在本協議執行前通過電子郵件或紙質形式交付給另一方或其代表。 「發起方股東協議」。

第2部分。交易描述.

2.1            合併根據本協議規定的條款和條件，在第一生效時間，第一合併子公司將與公司合併，第一合併子公司的獨立存在將終止。公司將繼續作爲第一合併中的存續公司（“第一步存續公司”根據本協議規定的條款和條件，在第二生效時間，第一步存續公司將與第二合併子公司合併，第一步存續公司的獨立存在將終止。作爲第二合併的結果，第二合併子公司將繼續作爲第二合併中的存續實體（“存續實體”).

2.2            合併的影響第一次合併應具有本協議及DGCL適用條款中規定的效力。 作爲第一次合併的結果，公司將成爲母公司的全資子公司。第二次合併應具有本協議及DGCL和DLLCA適用條款中規定的效力。

2.3            結束； 第一個生效時間；第二個生效時間。除非根據協議的規定提前終止 第十節， 並且需滿足或豁免所列條件 第七節, 第8節和頁面。第9節, the consummation of the Merger (the “結盤”) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in ‎6.19, 第8節和頁面。第9節, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the “交割日期在收盤日期之前的立即前，母公司應在特拉華州國務卿辦公室註冊該指定證書。在收盤時，（i）各方應通過簽署並向特拉華州國務卿辦公室提交一份有關合並的合併證書，滿足DGCL的適用要求，並以附件中所述的形式和實質進行， 附件 D-1 並納入本合同的（“首次合併證書”）和（ii）各方應通過簽署並向特拉華州國務卿辦公室提交有關第二次合併的合併證書，滿足DGCL和DLLCA的適用要求，並以附件中所述的形式和實質進行， 附件 D-2並納入本合同的（“第二份合併證書與首次合併證書一起，本證書將生效合併證書首次合併應在與特許部門和公司一起在Delaware州國務卿處提交該合併證書時生效，或者在該合併證書中指定的較晚時間生效（作爲合併生效的時間，被稱爲“First Effective Time第二次合併應在與特許部門和公司一起在Delaware州國務卿處提交第二份合併證書時生效，或者在該第二份合併證書中指定的較晚時間生效（作爲第二次合併生效的時間，被稱爲“第二 生效時間”).

2.4            組織文件; 董事和高級管理人員.

(a)            在第一個有效時間：

(i)First Step Surviving Corporation的公司註冊證書將在合併中被修改和重述，以按照第一合併證書的A表所示的內容進行，之後將根據DGCL和公司註冊證書進行修訂。

(ii)第一步生存有限公司的章程應與公司在第一有效時間之前立即生效的章程相同，直至根據DGCL和該章程隨後進行修改爲止；並

(iii)First Step Surviving Corporation的董事和高管，每位持有辦公室符合 First Step Surviving Corporation 的公司章程和公司規定，應爲公司在第一個生效時間之前指定的人員。

(b)在第二有效時間：

(i)            存續實體的組織文件應爲第二合併子公司的組織文件，即在第二生效時間之前即時生效的組織文件，直至之後按照特拉華公司有限責任公司法(DLLCA)和該組織文件進行修改；但是，在第二生效時間(作爲第二合併證書的一部分)時，應修改組織文件以(A)將存續實體的名稱更改爲「新月生物製藥營運公司，有限責任公司」，(B)經雙方父公司和公司協商一致的其他變更。

(ii)存續實體的有限責任公司協議應該被完全修改和重述，以與二次合併子公司的有限責任公司協議完全一致，該協議在第二生效時間之前有效，然後按照DLLCA和該有限責任公司協議的規定修改；但是，第二生效時間之後（但儘快），有限責任公司協議將被修改爲將存續實體的名稱更改爲「Crescent Biopharma Operating Company，LLC」。

(iii)          父公司的公司成立證書應與第二有效時間前的父公司公司成立證書相同，此後按照DGCL和該公司成立證書的規定進行修訂； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。， 在第二有效時間時，父公司應就其公司成立證書提交修訂，以(i) 將父公司的名稱更改爲「新月生物醫藥股份有限公司」，(ii) 進行納斯達克逆向拆股（如適用且必要）， (iii) 增加父公司授權發行的股票數量，該數量應在父公司和公司之間達成一致，足以完成擬議的交易，(iv) 將父公司納稅地從特拉華州重新設立到由公司確定的司法管轄區（即開曼群島或百慕大），以及(v) 進行 父公司和公司都同意的其他更改（此修訂，稱爲“家長憲章修正案”);

(iv)Parent的董事和高管，每人都將根據Parent的公司章程和公司規定擔任職務，如下所述 章節 ‎6.12；以及幫助孩子們跟蹤他們夏季口腔衛生習慣的材料。

(v)存續實體的董事和高管，每人應按照第二合併方的組織成立證書和有限責任公司協議的規定擔任職務章節 ‎6.12在生效後實施規定後章節 ‎6.12或者由母公司和公司相互同意的其他人員

2.5            公司、第一併購子公司和第二併購子公司股權證券轉換.

(a)在首次生效時間，根據合併，無需家長公司、合併附屬公司、公司或任何公司或家長公司股東採取進一步行動：

(i)            所有在首次生效時間之前作爲公司資本股票持有的庫藏股將被取消和註銷，並將不復存在，不交付任何對價；並

(ii)          主題 對 章節 ‎2.5(c)，（A）在第一個有效時間前即時發行的每股公司普通股（不包括根據2.5(a)(i) 取消的公司股票，也不包括持異議的股份）將僅轉換爲獲得家長公司普通股數量的權利等於 交易比率，以及（B）在第一個有效時間前即時發行的每股公司優先股（不包括 根據 章節 ‎ 和 排除要取消的公司資本股的股份) 章節 ‎2.5(a)(i)並且不包括異議股份）應當被轉換爲僅有權收取一定數量的母公司可轉換優先股，數量等於（x）交換率 除 （y）1,000（統稱爲“合併考慮”).

(b)如果第一生效時間之前公司資本股中的任何股份尚未獲得授予或者受限制的回購選擇權或風險，在任何適用的受限制股票購買協議或其他類似協議下，則以交換而來的父公司資本股將同樣尚未獲得授予並受到同等回購選擇權或風險的限制，並相應地標註適當的標籤。公司將採取一切必要行動，以確保在第一生效時間之後，父公司有權行使任何此類回購選擇權或其他在任何此類受限制股票購買協議或其他協議中規定的權利。

(c)在合併過程中，不會發行任何母公司股票的碎股，也不會發行任何此類碎股的證書或收據。任何本公司普通股持有人如果本應獲得母公司普通股的部分股份（按證書計算），將獲得由母公司提供的一份母公司普通股，而不是該碎股，並在按照交接信與任何相關文件的規定交出交接信時交付。 章節 ‎2.7 和其中要求的任何附隨文件： (i) 如果本公司普通股持有人應獲得的母公司普通股的碎股金額等於或超過0.50，則獲得一份母公司普通股；或(ii) 如果本公司普通股持有人應獲得的母公司普通股的碎股金額少於0.50，則不獲得任何母公司普通股，對於通過此類四捨五入消除的任何碎股不支付任何現金。任何本公司優先股持有人本應獲得的母公司優先股的碎股將與向該等人應發行的所有母公司優先股碎股相加，其餘的碎股將在按照和其中要求的任何附隨文件的規定交出交接信時四捨五入至母公司優先股的最接近整數股。 章節 ‎2.7 和其中要求的任何附隨文件： 將本公司優先股持有人本應獲得的任何母公司優先股的碎股與向該等人應發行的所有母公司優先股碎股相加，其餘的碎股將在按照和其中要求的任何附隨文件的規定交出交接信時四捨五入至母公司優先股的最接近整數股。

(d)所有板塊 在首個生效時間之前尚未到期的所有公司期權（包括任何服務提供商授予的期權）應按照 章節 ‎6.5(a)所有板塊 在首個生效時間之前尚未到期的所有公司warrants應按照章節 ‎6.5(b).

(e)每一股普通股，每股面值$0.001，由第一合併子公司在第一有效時間前發行並持續存在的股份都將轉換爲一股經有效發行、全額支付和免予清償的第一步存續公司每股面值$0.001的普通股。第一合併子公司的賬簿錄入股份證明對任何此類股份的所有權，在第一有效時間生效時，將證明對第一步存續公司的此類普通股的所有權。

(f)如果在本協議日期和首次生效時間之間，由於任何股息、細分、重新分類、資本重組、拆分（包括納斯達克倒轉拆分，只要這種拆分在計算交換比率時尚未被考慮在內）、股份合併或股份交換或其他類似變更，而導致已發行的公司資本股票或母公司資本股票變更爲不同數量的股份或不同類別的股份，交換比率應相應進行公允調整，以反映此類變更的必要程度，以便爲公司資本股票、公司期權、公司認股權證及母公司資本股票持有人提供與本協議所預期的同樣的經濟效果，以前述股息、細分、重新分類、資本重組、拆分、股份合併或股份交換或其他類似變更之前。 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。，但本文中的任何內容均不得解釋爲允許公司或母公司分別採取任何未經本協議明文允許或禁止的與公司資本股票或母公司資本股票有關的任何行動。

(g)在第二次生效時間，憑藉第二次合併，在母公司未採取任何行動的情況下，第一步存續公司、第二次合併子公司或其各自的股東，在第二次生效時間前已發行並持有的每股第一步存續公司股份將被取消和註銷，而不會轉換爲任何其他物品，也不會就此進行任何支付或分配。

2.6            公司轉讓股份登記簿的關閉在首個生效時間：(a) 所有公司股本即刻前的未發行股份應按照要求處理 第2.5(a)條所有持有公司股本的證書無權作爲公司股東，公司的股票轉倉簿應關閉，關於所有即刻前的未發行公司股本。首個生效時間後，不得在該股票轉倉簿上再進行任何未發行公司股本的轉讓。

2.7            公司股本的讓渡.

(a)在結束日期前，母公司和公司應共同選擇一家信譽良好的銀行，過戶代理或信託公司，以充當併購交易所代理（“交易所代理”）。在第一有效時間，母公司應向交易所代理存入代表依照 章節 ‎2.5(a)而發行給公司資本股的股份的電子持股證明。

(b)第一有效時間後，雙方應促使交易所代理給將公司股份轉換爲收到合併議價權利的股東郵寄以下文件：(i) 一份按照慣例形式幷包含股東大可合理規定之條文的投資傳遞函（包括確認僅在將公司股份證券交付給交易所代理時交付實物股份證券代表的公司股份（即“公司股份證券）風險及所有權僅在將此類公司股份證券交付給交易所代理時轉移，並且(ii) 換取電子記賬形式的母公司股份時損失風險和所有權轉移之說明。向交易所代理交換公司股份證券或公司股份未記名持有的合理所有權證明，連同如交易所代理或母公司可能要求的其他文件一同，以及合理填寫表格傳遞信函，交換之後：(A) 持有這種公司股份證券或公司股份未記名持有的人員有權收到代表合併議價的電子記賬股份（以母公司股份的整數股份計）以收到以下規定的權利 章節 ‎2.5(a)和 章節 ‎2.5(c)並且（B）公司股票證書或公司股本的非記名股票 如有符合本條的要求將被註銷。在按照本條的規定提供前，每一張公司股票證書或公司股本的非記名股票應被視爲自第一有效時間起僅代表 只有接收親屬資本股的賬面股份的權利。如果任何公司股票證書 已被遺失、盜竊或銷燬，親屬公司可能自行決定並作爲發帖的 條件，要求擁有此類遺失、盜竊或銷燬公司股票證書的所有者提供適用的宣誓書 就有關該公司股票證書，發帖保證親屬公司免受由於 有關該遺失、盜竊或銷燬公司股票證書或任何作爲交換而向其發行的親屬資本股所遭受的任何索賠。 章節 ‎2.7(b)，每張公司股票 證書或公司股本的非記名股票從第一有效時間起被視爲僅代表 只有接收合併對價的親屬資本股的賬面股份。如果任何公司股票證書 已遺失、盜竊或銷燬，親屬公司可能自行決定並作爲發帖的 條件，要求擁有此類遺失、盜竊或銷燬公司股票證書的所有者提供適用的宣誓書 就有關該公司股票證書，發帖保證親屬公司免受由於 有關該遺失、盜竊或銷燬公司股票證書或任何作爲交換而向其發行的親屬資本股的任何索賠。

(c)關於母公司資本股票，於第一生效時間後具有記錄日期的分紅派息或其他分配，不得支付給任何未交出公司股票證書持有人，直到該持有人交出該公司股票證書或公司資本股票的非記名股份，或按照本協議提供遺失或毀壞書面聲明爲止。 章節 ‎2.7 （屆時，該持有人將有權，受適用遺失財產（abandoned property）、未領取財產（escheat）或類似法律的影響，收取所有這些分紅和派息，無息）。

(d)            交易所代理持有的任何一家Parent Capital Stock股份，如果在Closing Date之後的日期180天時尚未分配給Company Stock Certificates持有人，將在Parent要求時交付給Parent，且任何尚未交出他們的Company Stock Certificates或根據此準則交出Company Capital Stock的無記名股份的Company Stock Certificates持有人 章節 ‎2.7 只能向Parent索賠Parent Capital Stock及與Parent Capital Stock相關的任何股票分紅或派息。

(e)任何人不應對任何公司股票證書的持有人或無證股票公司資本股的任何持有人，或對任何父公司資本股（或關於該資本股的分紅或派息）的持有人負責，也不應對根據任何適用的遺棄財產法、蕩產法或類似法律，向任何公職人員遞交的任何現金數額負責。

2.8            淨現金和公司估值的計算.

(a)不得晚於Closing之前的五(5)個工作日，母公司將向公司交付一份時間表(「父母淨現金時間表」)母公司淨現金時間表)詳細說明父母淨現金的成分，包括任何父母淨現金較低金額或父母淨現金較高金額(“母公司淨現金計算)截至預期Closing日期前一工作日的晚上11:59(“現金確定時間)由母公司首席財務官(或在該時刻沒有首席財務官的情況下，由母公司的首席財務和會計官確定)編制和認證。母公司應根據公司合理的要求，儘可能向公司提供(主要以電子形式)用於編制母公司淨現金時間表和備份材料的工作文件，如果公司合理要求，母公司應在合理時間內，並提前合理通知的情況下，安排公司對母公司的內部財務人員，會計師和顧問進行審計。母公司淨現金計算應包括母公司在現金確定時間確定的定義術語 章節 ‎1.1(a)在計算交換比率時是必要的。在交付母公司淨現金計劃後並在閉幕之前的期間，公司應有機會審查母公司淨現金計劃，並且母公司應合理配合公司誠信地回應公司關於母公司淨現金計劃的任何問題；但是，這絕不會限制或以其他方式影響公司根據本協議的補救措施，或使公司確認其中反映的金額的準確性。

(b)在收盤之前的不晚於五（5）個工作日，公司將向母公司交付一份安排（“公司估值 安排”），以合理詳細方式列明公司估值的主要元件的公司（“公司估值計算”）以及交付該安排的日期爲（“公司 估值交付日期”）截至預計收盤日前一個工作日的下午11:59，即（“公司 估值確定時間公司首席財務官（或若無首席財務官，則由公司信安金融和會計負責人）準備並認證。公司應在合理請求時向母公司提供用於編制公司估值表的工作文件和備用材料，並在合理時間內以及在合理通知下，如母公司合理請求，提供公司會計師和律師。在提交公司估值表後至交割之前的期間，母公司應有機會審核公司估值表，並公司應合理與母公司誠信合作，回答母公司提出的關於公司估值表的任何問題；但是，這無論如何不會限制或以其他方式影響母公司根據本協議或其他方式的補救措施，或構成母公司對其中所反映金額準確性的確認。

(c)不遲於現金確定時間後的三（3）個營業日內（該期間的最後一天，稱爲“回覆日期”），公司有權通過發出書面通知的方式對上級公司的淨現金計算的任何部分提出爭議（“爭議通知”）。 任何爭議通知應合理詳細地指明以及已知的任何擬定的對上級公司淨現金計算的修訂的性質和金額，並應附有合理詳細的支持這些修訂依據的材料。

(d)            在公司估值交付日期之後的不遲於三（3）個業務日內（該期間的最後一天，稱爲“公司 估值響應日期”），母公司應有權通過將書面通知交付給公司（一份“公司估值爭議通知”）來對公司估值計算的任何部分提出爭議。 任何公司估值爭議 通知應合理詳細地標明並在所知範圍內指出對公司估值計算的任何擬議修訂的性質和金額，並應附有合理詳細的支持這些修訂基礎的材料。

(e)如果，在回覆日期或之前，公司書面通知母公司，表示對母公司淨現金計算沒有異議，或者在回覆日期，公司未能如所述交付爭議通知書，那麼依照母公司淨現金計算表中的母公司淨現金計算結果被視爲在本協議目的而最終確定，並代表本協議中現金確定時間的母公司淨現金。 章節 ‎2.8(c)如果母公司淨現金計算表所述的母公司淨現金計算在本協議目的而已被最終確定，並代表本協議中現金確定時間的母公司淨現金。

(f)如果，在公司估值響應日期之前或之日，母公司書面通知公司表示對公司估值計算沒有異議，或者在公司估值響應日期當日，母公司未能按照規定提供公司估值爭議通知，則應視公司估值計算已被最終確定爲本協議目的，並代表公司估值爲本協議中公司估值確定時間的目的。章節 ‎2.8(d)則公司估值計算如公司估值表中所規定的應被視爲已最終確定，作爲本協議目的的公司估值，並代表公司估值確定時間的公司估值。

(g)如果公司在回應截止日期之前或之日交付爭議通知，則母公司和公司的代表應儘快會面，善意地嘗試解決爭議項，並就確定母公司淨現金的協商達成一致結論，該母公司淨現金金額應被視爲已最終確定，用於本協議目的，並代表本協議中現金確定時間的母公司現金。

(h)如果父公司在公司估值回應日期之前或之前提出公司估值爭議通知，則父公司的代表和公司的代表應及時會面，試圖善意解決有爭議的條款，並協商確定公司估值的各個元件的約定確定的公司估值金額應被視爲本協議目的而最終確定，代表了協議目的公司估值確定時間的公司估值。

(i)如果母公司和公司的代表無法協商就父母公司現金決定時間點的父公司淨現金達成一致的判斷 章節 ‎2.8(g)或者根據公司估值確定時間點的公司估值元件 章節 ‎2.8(h)在發出爭議通知或公司估值爭議通知後的三天內（或父母公司和公司可能相互同意的其他期限），如果關於父母公司淨現金或公司估值計算仍有爭議，則應將任何剩餘爭議提交給由父母公司和公司共同選定的具有公認國際聲譽的獨立核數師。如果各方無法在五（5）天內選擇獨立核數師，那麼父母公司或公司之後可以要求美國仲裁協會波士頓馬薩諸塞州辦事處參與。AAA請選擇由雙方共同選定的獨立核數師或由AAA選定的獨立核數師進行這樣的選擇，即“美國西南能源公司）。母公司和公司應及時向會計事務所交付用於準備母公司淨現金錶和糾紛通知以及公司估值表和公司估值糾紛通知的工作文件和備份材料，母公司和公司應盡商業上的合理努力，促使會計事務所在接受其選擇後的五個（5）個工作日內做出裁定。母公司和公司應有機會向會計事務所提交有關未解決爭議的任何材料，並與會計事務所討論問題； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。，在沒有父母公司和公司的代表在場的情況下，不得進行任何此類展示或討論。會計事務所的裁定應僅限於提交給會計事務所的分歧。由會計事務所制定的母公司淨現金數額或公司估值的元件的裁定應以書面形式交付給母公司和公司的每一方，對母公司和公司具有最終約束力，並且（除非有明顯錯誤）被視爲已經最終確定，用於本協議的現金確定時點的母公司淨現金數額或公司估值確定時點的公司估值元件。雙方應推遲交割，直至解決本協議中描述的事項 章節 ‎2.8(i)會計師事務所的費用和支出應按照Parent和公司無法成功爭辯的Parent淨現金額或公司估值金額（最終由會計師事務所判斷）與Parent淨現金額或公司估值元件的總爭議金額相比例分配。如果這個比例適用於現金確定時間的Parent淨現金的判斷或公司估值確定時間的公司估值元件的確定，則根據該條款解決後，即使交割日期晚於預期交割日期，各方也無需重新確定Parent淨現金或公司估值，但如果交割日期晚於預期交割日期30天，Parent和公司可以要求重新確定Parent淨現金或公司估值。 章節 ‎2.8(i)適用於現金確定時間的Parent淨現金或公司估值確定時間的公司估值元件的判斷，根據該條款解決後，即使交割日期晚於預期交割日期，各方也無需重新確定Parent淨現金或公司估值，但如果交割日期晚於預期交割日期30天，Parent和公司可以要求重新確定Parent淨現金或公司估值。 章節 ‎2.8(i)各方在根據此條款解決事宜後，即使交割比預計交割日期晚，也無需重新確定Parent淨現金或公司估值，但如果交割日期晚於預期交割日期30天，Parent和公司可以要求重新確定Parent淨現金或公司估值。

2.9            進一步行動如在第一有效時間後的任何時間內，生存實體確定有必要或有必要執行本協議目的或使生存實體充分享有公司的所有權利和財產，則生存實體的官員和董事將被充分授權，並將以商業上合理的努力（以公司名義、以第一次合併子公司名義、以第二次合併子公司名義、以生存實體名義以及其他方式）採取此類行動。

2.10            稅務處理意願各方承認並同意，就美國聯邦（及適用的州和地方）所得稅目的而言，本次合併旨在符合《法典》第368(a)條的重組定義（“稅務處理意願”）。各方視本協議爲根據《財政部法規》第1.368-2(g)和1.368-3條的「重組計劃」採納。

2.11            預扣稅款。每個交易代理商、母公司和存續實體均有權從根據適用法律應扣除或代扣的任何對價中扣除和代扣所需的金額； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時； 交易代理商、母公司和存續實體將盡商業上的合理努力，立即通知相關人員有意扣減任何部分該等對價，並與相關人員合作，在適用法律允許的範圍內減少或消除任何該等代扣。在扣除或代扣並匯給適當政府機構後，該等金額在本協議下應被視爲已支付給本應支付給該等金額的人員。根據本協議支付的構成員工稅務目的的所有款項應通過存續實體或母公司的工資支付。

2.12            評估權.

(a)儘管本協議的任何規定與之相反，公司的股本股票即在第一次生效時間之前即刻發行並由行使並完善了根據DGCL拍賣權的股東或受益所有人所持有的（統稱爲“異議股份”不應轉換爲或代表有權接收根據 章節 ‎2.5 的合併對價。這些股東或受益所有人有權按照DGCL規定收取他們持有的公司股本股票的公允價值，直到這些股東或受益所有人未能完善或有效撤回或以其他方式失去根據DGCL的拍賣權爲止。所有未能完善或有效撤銷或失去其根據DGCL對公司股本股票的評估權的股東或受益所有人（不論是在第一次生效時間前還是在第一次生效時間後）持有的所有拒絕的股份，據此將被視爲自該等股東或受益所有人在方式規定的情況下交出這些拒絕的股份時，作出爲，在第一次生效時間，有權接收根據這些拒絕的股份而成爲可兌換的，並且有權接收的合併對價（不含利息）。 款項 ‎2.520,200,000‎2.7.

(b)公司應及時向母公司書面通知公司收到的股東抗議或受益所有人提出的任何要求、撤回此類要求以及公司收到的任何其他文件，以及與此類要求相關的任何重要函件，並且母公司有權參與所有與這些要求有關的談判和程序。公司不得在未經母公司事先書面同意（不得無故拖延、阻礙或設定條件）的情況下，就此類要求進行任何支付，或解決或提議解決任何此類要求，或批准任何此類要求的撤回或同意執行前述任何行動。

第3節。 公司的陳述和擔保.

除了公司交付給母公司的書面披露文件之外，公司向母公司和併購附屬公司保證：公司披露函與本協議同時執行的書面披露文件除外，公司向母公司和併購附屬公司保證如下：

3.1            由 組織; 子公司.

(a)公司是根據其所在管轄區域法律成立或其他合法實體，合法存在並處於良好狀態，並具有一切必要的權力和權限：(i) 根據目前業務運營的方式開展業務，(ii) 擁有或租賃和使用當前擁有或租賃和使用的財產和資產，和(iii) 履行其受約束的所有合同下的義務。

(b)            公司已獲得合法許可並具備從事業務的資質，在所有業務性質及目前業務進行所需的管轄權下，良好地處於合法地位（在該管轄區域適用的範圍內），除了在未獲得此類許可或資質的管轄區域，其單獨或共同未取得資質的情況在合理預期範圍內不會對公司產生重大不利影響。

(c)            公司沒有附屬公司，並且公司不擁有任何其他實體的股權或成員權益，也不直接或間接地控制任何其他實體的任何性質的權益、所有權或利潤分享權益。公司不是，並且從未直接或間接地成爲任何合夥企業、合資企業或類似業務實體的當事方、成員或參與方。公司沒有同意或有義務進行或受制於可能使其有義務進行未來投資或對其他實體進行資本貢獻的任何合同，也沒有給予其有義務進行未來投資或對其他實體進行資本貢獻的約束。公司從未是任何合夥企業、有限合夥企業或其他實體的普通合夥人，也從未對任何普通合夥企業、有限合夥企業或其他實體的任何債務或其他義務承擔過責任。

3.2            組織文件公司已向母公司交付了公司的組織文件的準確完整複印件。 公司在任何重大方面不違反或違背其組織文件。

3.3            權威性； 協議的約束力. 公司擁有一切必要的公司權力和授權，以簽訂並履行本協議項下的義務，並完成預期的交易。 公司董事會已經（i）確定預期的交易對公司及其股東公平、明智並符合最佳利益，（ii）批准和宣佈本協議和預期的交易的明智之舉，並（iii）決定在本協議的條款和條件下建議，股東們投票通過本協議並因此批准預期的交易。 本協議已由公司妥善簽署和交付，並假定母公司、第一合併子公司和第二合併子公司經過適當授權、簽署和交付，構成公司的合法、有效和具有約束力的義務，依據協議條款對公司具有強制執行力，但須受到可執行性例外情形的限制。

3.4            所需表決股東經公司登記日持有的大多數公司股份股東投贊成票（或書面同意），按轉換基礎單一類別表決，和持有公司種子優先股登記日持有並有權對此進行表決的大多數公司種子優先股股東投贊成票，按獨立類別表決，是採納和批准本協議以及批准擬議交易（統稱“需要公司股東投票”).

3.5            非違反； 同意.

(a)在獲得必要的公司股東投票、符合《HSR法案》（如適用）的任何適用要求以及提交特拉華州公司法或深圳經濟特區公司法規定的合併證書和指定證書後，（x）公司簽訂、交付或履行本協議，以及（y）完成擬議交易，均不會直接或間接（無論有無通知或經過時間）：

(i)違反公司組織文件的任何規定，與之衝突或導致違反。

(ii)違反，與或導致公司受限制或使用的資產受限的任何法律或任何給予任何政府機構或其他人士挑戰擬議交易或行使任何救濟或依法獲得任何救濟權力的法律或任何命令衝突;

(iii)違反，衝突或導致違反公司任何條款或要求，或使任何政府機構有權撤銷、撤回、暫停、取消、終止或修改公司持有的或與公司業務或公司擁有、租賃或使用的任何資產相關的任何政府授權。

(iv)違反，與任何公司物資合同的任何規定衝突或導致違反或違約或導致默認，在任何公司物資合同的任何條款下給任何人權利：(A) 宣佈違約或行使任何公司物料合同下的任何補救措施，(B) 任何實質性支付，退款，退款，處罰或交貨時間表變更，(C) 加速任何公司物料合同的到期日或履行，或(D) 取消，終止或修改任何公司物料合同的任何條款，但在任何非重大違約，違約，處罰或修改情況下除外；或

(v)在對公司擁有或使用的任何資產強加或設立任何擔保（除了被允許的擔保）的情況下

(b)            除(i)必要的公司股東投票，(ii)根據DGCL或DLLCA向特拉華州州務卿登記合併證和指定證書，(iii)符合適用的HSR法案要求(如適用)和(iv)根據適用的聯邦和州證券法要求可能需要的批准、豁免、批准文件、授權、註冊、聲明和提交外，公司無需向任何涉及(x)執行、交付或履行本協議或(y)完成擬議交易而必須提交文件或發出通知或取得任何人的同意。

(c)沒有州接管法規或類似的法律適用或據稱適用於合併、本協議、公司股東支持協議或任何擬議交易。

3.6            資本

(a)公司的授權股本包括（i）40,000,000股公司普通股，截至本協議日期已發行並流通的股份爲27,049,180股；（ii）20,000,000股公司優先股，其中20,000,000股已指定爲種子優先股，並截至本協議日期已發行並流通的股份爲20,000,000股。公司沒有持有任何股份在其庫存中。至本協議日期，公司的股本由個人持有，並且數量如下所示。 章節 ‎3.6(a)公司披露函的第 項進一步說明了每位個人（i）持有的股份數量和個人姓名，（ii）這些股份的類別和系列，（iii）代表這些股份的適用記賬帳戶數量或代表這些股份的證書數量，（iv）該人員是否是或曾經是僱員，以及（v）該人員的住宅地。每股公司優先股可轉換爲一股公司普通股。對於公司股本沒有宣佈或應計但尚未支付的股息，公司從未宣佈或支付過任何股息或其他分配。

(b)            所有板塊 如所述。 章節 ‎3.6(a)於公司披露信函 中載明的所有傑出公司股本均已得到妥善授權和有效發行，已全部支付並且無需進一步徵稅，並且除組織文件或適用證券法規定的負擔外，不附加任何擔保。任何尚未發行的公司股本均無權或受預先購買權、參與權、維持權或任何類似權利的約束，也不受任何優先購買權利益或任何優先購買權的約束。除本協議所約定外，沒有任何公司合同涉及對公司股本的投票或登記，也沒有任何公司合同限制任何人購買、出售、抵押或以其他方式處置（或就公司股本授予任何期權或類似權利）。公司無義務且也未受約束，根據公司可能需履行或受任何合同的約束而成爲有義務回購、贖回或以其他方式取得任何尚未發行的公司股本或其他證券。 章節 ‎3.6(b於公司披露信函的2) 中準確而完整地描述了公司就公司股本（包括根據行使期權而發行的股份）持有的所有回購權利，並指明目前可以行使哪些回購權利。

(c)除公司股票計劃外，且除所述之外 章節 ‎3.6(c)公司沒有任何股票期權計劃或任何其他計劃、方案、協議或安排，爲任何個人提供基於股權的報酬。 章節 ‎3.6(c)關於截至本協議日期尚未行使的每個公司期權，披露函第 部分概述了以下信息：（i）持有人的姓名，（ii）截至本協議日期有關的公司普通股數量，（iii）公司期權的行權價格，（iv）授予公司期權的日期，（v）適用的獲股計劃表，包括任何加速條款，（vi）公司期權到期日期，（vii）是否擬定爲「激勵性股票期權」（根據法典定義）或非資格股票期權，以及（viii）在公司期權情況下，授予該公司期權的計劃。公司已向母公司提供了關於公司已發放基於股權獎勵的股權激勵計劃的準確和完整副本，以及證明已向董事會和股東展示公司股票計劃及其任何修訂的所有授予協議樣本。

(d)除了尚未行使的公司期權或在公司披露函的約定外，沒有任何待議事項：（i）沒有待行使的或出售的認購權，選項，看漲，認股權證或其他公司股票或其他證券的權利（無論是否當前可行使），（ii）沒有待兌現爲公司股本或其他公司證券的任何股票轉換權，工具或債務，（iii）沒有股東權益計劃（或通常稱爲"毒丸"的類似計劃）或根據其公司有義務出售或以其他形式發行任何公司股票或任何其他證券的合同，（iv）沒有可能導致或構成任何人聲稱有權取得或收到公司股票或其他證券的任何股票的狀況或情形。關於公司的任何優先或已授權的股票增值權，虛擬股票，利潤分配或其他類似權利與公司有關。 章節 ‎3.6(d)公司披露函的第 ___ 頁，沒有：（i）公司股票或其他證券的待行使的認購權，選項，看漲，認股權證或權利（無論是否當前可行使），（ii）任何待兌現爲公司股本或其他證券的股票轉換，工具或債務，（iii）股東權益計劃（或通常稱爲"毒丸"的類似計劃）或公司根據合同有義務出售或以其他方式發行公司股票或其他證券，（iv）可能引發或提供據稱其有權取得或接收公司股票或其他證券的任何人提出索賠的條件或情況。關於公司不存在任何未清償或已授權的股票增值，虛擬股票，利潤分配或其他類似權利。

(e)所有未償還的公司股本、公司期權和其他證券均已依法發行和授予，符合（i）所有適用證券法律和其他適用法律的要求和（ii）適用合同中規定的所有要求。

(f)公司股本是非記名股。

3.7            財務報表.

(a)公司建立了一套內部會計控制系統，旨在提供合理保證：（i）交易根據管理層的一般或特定授權進行，（ii）交易按照需要記錄，以便按照GAAP準則編制公司的基本報表並維護公司資產的責任，（iii）只有按照管理層的一般或特定授權才允許訪問公司的資產，以及（iv）記錄公司資產的責任與定期檢查的現有資產進行比較，並針對任何差異采取適當措施。公司持續保持着與類似私營公司的財務報告相一致的內部控制，可合理保證財務報告的可靠性以及爲外部目的編制基本報表。

(b)            章節 ‎3.7(c)公司披露信函清單中列出的所有事項，並且公司向母公司交付了創建或管理所有證券化交易和「資產負債表之外安排」（根據《證券交易法》第303條（c）條規定）的準確和完整文件副本。

(c)關於財務報告或會計政策和實踐的正式內部調查尚未在公司首席執行官、致富金融(臨時代碼)或公司總法律顧問、公司董事會或其任何委員會的指示下討論、審核或啓動。公司或其獨立核數師未識別出：(i) 公司內部會計控制系統的設計或操作存在任何重大缺陷或實質性弱點，(ii) 涉及公司、公司管理層或參與財務報表編制或公司使用的內部會計控制的其他員工的任何欺詐，無論規模大小，(iii) 關於前述任何事宜的任何主張或指控。

3.8            變化的缺失除《基本報表》上所述之外，公司在交易中未僱用任何經紀人或中介。 章節根據公司披露函件第3.8節，在公司成立之日和本協議簽訂日期之間，公司只在業務常規範圍內開展業務（除了執行並履行本協議以及與此相關的討論、談判和交易），未發生任何（a）公司重大不利影響或（b）可能需要根據本協議第5.2（b）節徵得母公司同意的行動、事件或情況。 根據本協議第5.2（b）條本協議簽署和交付後，若發生此類行動、事件或情況，可能需要母公司同意。

3.9            未披露的負債缺失自成立以來，公司並無任何形式的責任、債務、義務、費用、索賠、缺陷、保證或背書，無論已歸屬、絕對、或未來可能發生等（統稱「負債」）負債），除以下情況外：(a) 基本報表中披露、體現或留存的負債（或將披露、體現或留存）；(b) 自此日期以來公司在正常業務經營中發生的正常且經常性負債（其中無一違反任何合同、擔保、侵權或違法行爲）；(c) 公司合同下的義務履行負債；(d) 與本次擬定交易相關的負債；以及(e) 第 3.9 節中描述的負債 第3.9節公司披露函的附錄

3.10            資產標題公司擁有，並擁有所有實體財產或實體資產及用於其業務或運營中的設備的良好和有效所有權，或者在租賃財產和資產的情況下，擁有合法的租賃權益，包括公司賬簿和記錄中顯示爲公司所有的所有實物資產。所有這些資產均由公司擁有，或者在租賃資產的情況下，公司享有清晰的權利，除了允許的負擔外，沒有其他任何負擔。

3.11            房地產; 租賃權公司並不擁有，也從未擁有過任何房地產，也沒有與公司購買或賣出任何房地產的協議。公司已向母公司提供了（a）公司直接或間接持有有效租賃權益的所有房地產的準確完整清單，以及公司佔有或租賃的其他任何房地產並（b）有關任何此類房地產的租賃合同副本。（“公司房地產租賃”），每份租賃合同均有效且生效，沒有公司存在任何重大違約，也沒有根據公司或公司了解到的其他各方的了解，不存在現有的重大違約。

3.12            知識產權.

(a)            章節 ‎3.12(a)公司披露函的所有板塊是所有公司註冊知識產權的準確、真實和完整清單。

(b)            章節 ‎3.12(b)公司披露信中準確地識別了以下事項： （i）根據任何公司知識產權被授權給公司的所有公司合同（除了（A）僅以可執行或目標代碼形式​​授權的任何非定製軟件，根據非排他性內部使用軟件許可和與此類軟件相關的其他知識產權，並且未納入或對公司產品或服務的開發，製造或分發具有重要意義的任何內容， (B)輔助於購買或使用服務，設備，試劑或其他材料的非排他性許可的任何知識產權， (C)根據保密協議提供的任何機密信息以及（D）公司與其員工之間的公司標準格式協議），和（ii）公司獲得的許可是否具有排他性或非排他性。

(c)            章節 ‎3.12(c)披露信函中明確標識了每份公司合同，根據這些合同，任何人已被授予公司知識產權的許可或允諾不起訴，或者已經獲得或取得了任何公司知識產權的權利（無論目前是否可行使），除了（i）根據保密協議提供的任何機密信息和（ii）獨家授權給學術合作者、供應商或服務提供商的任何公司知識產權，目的僅是使這些學術合作者、供應商或服務提供商能夠爲公司的利益提供服務。

(d)公司並非受約束，也沒有任何公司知識產權受約任何合同的約束或其他規定，該約定或其他規定在任何地方限制或限制公司使用、開發、主張或執行任何公司知識產權的能力。

(e)公司獨家擁有所有公司知識產權的所有權利、權益（除了（i）授權給公司的公司知識產權，或在公司披露函中明確標識的共同擁有權利 章節 ‎3.12(e)公司披露函中的條款，（ii）任何未經定製的軟件，是根據非排他性的內部使用軟件許可證以可執行或目標代碼形式授權給公司，並與此類軟件相關的其他知識產權，且不包括在任何公司產品或服務的開發、製造或分銷中，或對其具有重要影響的任何知識產權，以及（iii）任何在購買或使用設備、試劑或其他材料時附帶許可的非排他性基礎上知識產權），在所有情形下，均沒有任何除了允許的擔保以外的 擔保。 無限制前述內容的範圍：

(i)所有文件和工具已被有效簽署、交付並及時提交給相關政府機構以註冊、申請或更新公司註冊的知識產權。

(ii)每個公司的僱員或承包商，涉及爲公司創造或開發任何知識產權的人，都已簽署有效、可執行的協議，包含將這些知識產權現有轉讓給公司的條款，以及保護公司商業祕密和機密信息的保密條款。

(iii)據公司了解，公司目前或曾經的股東、高管、董事或僱員均不存在對公司所擁有的任何公司知識產權聲稱、權利（無論當前是否可行使，或將來可行使）或利益的情況。據公司了解，公司的僱員中（a）未受任何限制他/她爲公司履行職責的合同約束或其他限制；或（b）未違反與任何前僱主或其他個人簽訂的與公司所擁有的公司知識產權或保護包括公司知識產權的商業祕密和機密信息的保密協定有關的任何協議。

(iv)未使用任何政府機構或大學、學院、研究機構或其他教育機構的資金、設施或人員，直接或間接地，開發或創建公司擁有股權的全部或部分知識產權，但除了如下情況：不導致該政府機構或機構擁有這些公司知識產權或享有因實踐這些公司知識產權而獲得版稅或其他報酬的權利的資金或使用設施或人員，截至本協議簽署日期。

(v)公司已採取合理措施，以維護並保護並執行其對所有專有信息的權利，該公司持有的或聲稱持有的信息被視爲保密或商業祕密。

(vi)公司尚未將任何公司知識產權的所有權轉讓給其他人，也沒有同意將任何公司知識產權的所有權轉讓給其他人。

(f)公司已向母公司交付或提供所有知識產權協議的完整準確副本。就每份知識產權協議而言：(i) 每份協議對公司具有法律效力且完全有效， (ii) 公司未收到任何有關終止或取消的書面通知，或收到任何有關違約或違約的書面通知，而此違約尚未被糾正或放棄，以及(iii) 公司及據公司所知，相關各方均未在任何重大方面違反或違約。

(g)公司目前銷售或正在開發的任何產品的製造、營銷、銷售、進口、使用或預期使用或其他處置行爲均不違反公司與任何第三方之間的任何許可證或協議，且據公司所知，也不侵犯或盜用任何其他個人的有效和已發行的專利權或其他知識產權，該侵權或盜用理應預料會對公司產生重大不利影響。據公司所知，沒有第三方侵犯公司所擁有的專利權，或以其他方式違反任何涉及公司知識產權的協議。

(h)截至本協議簽訂之日，公司未參與任何法律訴訟（包括但不限於針對任何專利或其他政府機構的反對、干擾或其他訴訟），爭議該公司知識產權的有效性、可強制執行性、索賠構造、所有權或使用權、銷售、提供銷售、許可或處置公司任何知識產權的權利。公司沒有收到任何書面通知聲稱公司的任何知識產權或根據其聲稱的產品、方法或過程的使用、銷售、提供銷售、許可或轉讓侵犯、侵佔或違反任何其他人的權利，或者公司以其他方式侵犯、侵佔或以其他方式違反任何人的知識產權。公司的任何知識產權均不受任何政府機構的未結案命令、裁定書、法令或協議的限制，該命令限制公司開發利用任何公司知識產權。

(i)公司註冊IP的每一項內容，一直以來都按照所有適用法律進行歸檔和維護，所有必須在適當期限內進行的申報、付款和其他操作，以維持該公司註冊IP的全部生效和效力，都已經完成。據該公司所知，所有已頒發或授權的公司註冊IP都是有效的且可強制執行的。

(j)            據公司所知，公司擁有、使用或申請的任何商標（無論是否註冊）或商號均不會與其他任何個人擁有、使用或申請的任何商標（無論是否註冊）或商號發生衝突或干擾。公司擁有或聲稱擁有所有權利的任何商標（無論是否註冊）所關聯的或固有的商譽未受損，公司按照通用會計準則確定。

(k)除了 如中所述 章節‎3.12(b), ‎3.12(c)要麼 ‎3.12(k)該公司的 披露信函或在正常業務過程中籤訂的 「現成」 許可協議中包含的披露信 公司，(i) 公司不受任何合同的約束，不得向任何其他人提供賠償、辯護、使其免受傷害或向任何其他人提供補償 從整體上看，尊重對公司具有重要意義的任何知識產權侵權、挪用或類似索賠 以及 (ii) 公司從未承擔或同意解除任何現有或潛在的責任或以其他方式承擔責任 他人侵犯、挪用或違反任何知識產權，包括假設、協議或 責任自本協議簽訂之日起仍然有效。

(l)公司沒有參與任何合同，由於執行、交付和履行本協議的結果，將導致授予任何公司知識產權的任何許可或其他權利，違反、違約或終止與任何公司知識產權相關的該等合同，或損害公司或存續實體及其子公司使用、賣出或許可或有效執行任何公司知識產權或其部分的權利，除非發生任何此類授予或損害，該授予或損害合計後果不會被合理預期導致公司重大不利影響。

3.13            協議、合同和承諾.

(a)            章節 ‎3.13(a)公司披露函的清單列出了本協議簽訂日期生效的以下公司合同（每個合同名稱爲“公司 物料合同全部協議稱爲「」。公司重要合同”):

(i)任何與非業務常規過程中締結的賠償或擔保協議有關的公司合同

(ii)每一份公司合同均含有(A)限制公司或存續實體從事任何業務或與任何個人競爭，或限制公司產品或服務的開發、製造或分銷的任何契約；(B)任何最優惠定價安排，(C) 任何排他性條款 或 (D) 任何禁止招攬條款。

(iii)每個 公司合同（A）根據該合同，任何個人向公司授予獨家許可使用任何知識產權；或（B）根據該合同，公司向任何個人授予獨家許可使用任何公司知識產權；

(iv)每份公司合同均涉及超過10萬美元的資本支出，並要求根據其明文條款在本協議日期之後進行支付，且不可無罰款取消；

(v)           each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;

(vi)          each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;

(vii)         each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;

(viii)        each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;

(ix)          each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;

(x)每家公司合同（包括與公司爲一方或與其資產與財產受約束的合同）中，牽涉到公司每年支付義務或向其支付超過10萬美元的合同；

(xi)每份公司合同的簽訂，解決任何法律訴訟或其他爭議，根據該合同，公司或其任何子公司有超過10萬美元的尚未償付的義務；

(xii)         任何其他不可因公司意願而隨意終止的公司合同（沒有違約或支付）。按照任何此類協議、合同或承諾，公司自本協議日起的付款或收款金額總計超過$100,000，或本協議日後的義務總額超過$100,000或對公司整體業務或運營至關重要的合同；或

(xiii)公司 房地產租賃。

(b)公司已向母公司提供準確完整的所有公司實質合同副本，包括所有修改。沒有公司實質合同是非書面形式的。截至本協議日期，公司未違反任何公司實質合同的條款或條件，也未收到任何其他方違反合同或違約的通知。如果該公司實質合同規定了糾正期限，則公司或其他方未糾正違約，違反或違約，以致任何其他方或公司（視情況而定）被允許修改、取消或終止任何該等公司實質合同，或者允許任何其他方尋求可能會對公司產生實質不利影響的損害賠償。截至本協議日期，每份公司實質合同對於公司而言均有效、具有約束力、可執行且有效，但需排除可執行性例外。沒有任何個人正在重新談判，或根據任何公司實質合同的條款有權更改公司根據任何公司實質合同支付或應支付的任何重大金額或其他任何公司實質合同的任何其他重大條款或規定。

3.14            合規; 許可證; 限制.

(a)            公司已經且一直以來都嚴格遵守所有適用法律。沒有任何政府機構的調查、索賠、訴訟、審計、命令或其他法律程序或訴訟，或者據公司所知有威脅要對公司採取行動。沒有對公司具有約束力的協議或命令（i）已經或有理由預期會禁止或實質上影響公司的任何業務實踐、公司收購實質財產或公司當前經營的業務，（ii）合理可能對公司履行本協議項下的任何承諾或義務產生不利影響，或（iii）合理可能阻止、延遲、使之非法或者以其他方式干擾擬議的交易。

(b)除美國食品藥品監督管理局（或任何取代者）（“FDA”）或其他負責管理藥品或器械產品的開發、測試、製造、加工、儲存、標籤、銷售、營銷、廣告、分銷、進口或出口的類似的政府機構（“藥品/器械監管機構”），公司擁有目前進行中的業務的所有必要的政府許可公司及其子公司持有公司及其子公司業務運營所需的所有政府許可、授權、許可證、批准、豁免、讓步和命令，包括任何政府機構根據適用法律及法規要求的、所需的所有保險和再保險許可證件（統稱爲「公司許可證」）。”). 章節 ‎3.14(b)公司披露函的第N部分標識出每一個公司許可證。公司嚴格遵守公司許可證的條款。據公司所知，沒有任何法律程序正在進行，也沒有威脅要廢除、大幅限制、暫停或實質修改任何公司許可證。每一個公司許可證的權利和利益將在第二生效時間之後立即對擬合併實體或其附屬公司（如適用）可獲得，條件性質大致與本協議簽署日期之時的公司享有的相同，並在第一生效時間之前一直保持不變。

(c)公司目前沒有任何待審的法律訴訟，也沒有據公司了解，因涉嫌違反《聯邦食品、藥品和化妝品法案》、《FDCA公共衛生服務法案》、FDA下屬的法規、《受控物質法案》或藥品/器械監管機構頒佈的任何其他類似法律而受威脅的情況。PHSA藥物/器械監管機構制定的任何其他類似法律。

(d)公司持有所有必要的政府授權可以由任何藥品/器械監管機構簽發，這些授權對公司目前開展的業務以及產品或產品候選品的開發、測試、製造、加工、儲存、標籤、銷售、營銷、廣告、分銷、進口或出口（目前進行）均爲必要。公司產品候選品證券法1933年修改公司監管許可證”）且沒有這樣的公司監管許可證已被（i）撤銷、撤回、暫停、取消或終止，或（ii）以任何不利的方式進行修改，除了不重大的不利修改。 章節 ‎3.14(d)公司披露函的「公司監管許可證」，已經準確識別了每一種公司監管許可證。公司已及時地保持並且在所有重要方面遵守公司監管許可證，而且未收到任何來自任何藥品/器械監管機構的關於（A）任何重大違反任何公司監管許可證條款或要求 或（B）任何公司監管許可證的撤銷、撤回、暫停、取消、終止或重大修改的書面通知、函件或據公司所知的其他通訊。公司已向母公司提供了所有母公司要求的公司所掌握或控制的與重要公司產品候選品有關的信息，以及與公司產品候選品的開發、測試、製造、加工、儲存、標籤、銷售、營銷、廣告、分銷及進口或出口有關的材料，包括但不限於以下完整副本（如有）：（x）不良事件報告; 臨床前、臨床和其他研究報告和重要研究數據;檢查報告、不良發現通知、無標題信函、警告信、備案和信函，以及向任何藥品/器械監管機構的信函和會議紀要和（y）同其他政府機構的類似報告 、重要研究數據、通知、信函、備案、通信和會議紀要。所有此類信息在所有重要方面都是準確且完整的。

(e)所有臨床、臨床前和其他研究和測試由公司代表或贊助的，或公司所參與的，包括公司產品候選品牌參與的，均在所有實質方面依照標準醫療和科學研究程序進行，基本符合適用的方針，在所有實質方面遵守適用的藥品/器械監管機構和其他適用法律的相關規定，包括21 C.F.R.第11、50、54、56、58、312和812部分。公司未收到任何藥品/器械監管機構、政府當局、審查委員會、倫理委員會或安全監測委員會發出的任何書面通知、函電或其他通信，要求或據公司所知威脅要採取行動，對公司或其目前產品或產品候選品參與的臨床研究採取臨床保留訂單，或以其他方式終止、延遲或暫停。此外，公司所知，在由公司代表或據公司所知由公司代表開展的任何臨床研究中，沒有任何臨床研究者、研究人員或臨床人員被取消參與公司產品候選品品牌相關研究的資格，公司所知，並不存在實施取消這些臨床研究者、研究人員或臨床人員資格的行政措施的威脅或者在進行中。

(f)公司本身或據公司所知，與任何公司產品候選品相關的任何合同製造商並未成爲FDA根據其《欺詐、不實陳述相關重要事實、賄賂及非法回扣》最終政策（見56 Fed. Reg. 46191（1991年9月10日）及任何修改）或任何其他藥物/器械監管機構根據類似政策所進行的正在進行或據公司所知受到威脅的調查對象。公司本身未發生且據公司所知，任何合同製造商及其各自的高管、僱員或代理人與任何公司產品候選品相關並未實施任何行爲、作出任何聲明或未能作出任何聲明，這些行爲、聲明或未能作出聲明方面均違反FDA的《欺詐、不實陳述相關重要事實、賄賂及非法回扣》最終政策及任何修改或任何其他藥物/器械監管機構的類似政策。公司本身或據公司所知，任何與任何公司產品候選品相關的合同製造商或其各自的高管、僱員或代理人目前未被取消資格，未被定罪或未從事可能導致根據(i) 21 U.S.C. 第335a 款或(ii) 任何類似適用法律進行取消資格處罰或禁止行爲。據公司所知，不存在針對公司、公司產品候選品的任何合同製造商或其各自的高管、僱員或代理人正在進行或受到威脅的取消資格或禁止索賠、行動、訴訟或調查。

(g)所有板塊製造業-半導體操作均已經在公司知情情況下進行，或者爲公司利益與任何公司產品候選人有關，且在所有重大方面符合適用法律，包括FDA的當前良好製造規範標準，包括21 C.F.R. 210、211和600-610部分以及在美國以外國家政府當局制訂的規定要求及其相應的對應物。

(h)公司或公司知情的合同製造商或實驗室的任何製造業-半導體公司產品候選者，（i）沒有受到藥物/器械監管機構關閉或進出口禁令的影響，也沒有受到（ii）FDA 483表格、違規通知、警告信、無標題信函或FDA或其他藥物/器械監管機構的類似函件或通知，指稱或主張未遵守任何相關法律，且該類情況尚未得到滿足或被相關藥物/器械監管機構關閉，公司知情的情況是，FDA或其他藥物/器械監管機構也沒有考慮此類行動。

3.15            法律訴訟; 命令.

(a)            公司沒有未決的法律訴訟，並且據公司了解，沒有任何人以書面形式威脅要提起任何法律訴訟： (i) 涉及公司或其子公司或任何公司關聯方（以其爲身份）或公司擁有或使用的任何主要資產或其子公司的任何法律訴訟，或 (ii) 挑戰，或可能導致阻止，延遲，使非法或以其他方式干擾擬議的交易。

(b)公司或其任何子公司，或公司或其任何子公司擁有或使用的主要資產，均不受任何訂單限制。據公司了解，沒有高管或公司重要員工受任何要求的約束，該要求禁止該高管或公司關鍵員工從事或繼續從事與公司或其任何子公司或公司或其任何子公司擁有或使用的主要資產相關的任何行爲，活動或做法。

3.16            稅務事項.

(a)公司已及時提交（或使提交）所有所需根據適用法律提交的所得稅申報和所有其他重要稅務申報（考慮到適用的延期）。所有這類稅務申報在所有重要方面均真實、正確且完整。除了不重大的例外，任何政府機構均未在公司未提交稅務申報的司法管轄區提出要求認定公司受到該司法管轄區稅務管轄。

(b)所有板塊 公司應付的全部稅款（無論是否顯示在任何稅務申報表上）均已按時支付（考慮到任何適用的延期申報）。

(c)公司已經扣繳並支付給相關政府機構所有應扣繳並支付的主要稅項，包括支付或應付給任何員工、獨立承包商、債權人、股東或其他第三方的任何金額。

(d)公司的資產上沒有任何涉及大額稅款的擔保（《允許擔保》定義中第（a）款描述的其他擔保除外）。

(e)就公司而言，沒有任何政府機關書面主張、提出或評定的對該公司涉及的稅收金額存在未及時全額支付的缺陷。就該公司而言，並無任何未決（或基於書面通知，受到威脅的）涉及公司稅收責任的重大審計、評估、檢查或其他行動。該公司尚未就任何涉及重大稅收金額的訴訟時效或就當前生效的任何重大稅務評估或缺陷的時間延期，授予豁免。

(f)公司在過去五（5）年內未被視爲《法典》第897（c）（2）節規定的美國房地產控股公司。

(g)公司未參與任何稅收分配、稅收共享或類似協議（包括賠償安排），除了在業務正常進程中籤訂的慣常商業合同，其主要目的並不涉及稅收（“業務正常合同”).

(h)公司不是聯邦聯合報稅團體的成員（除了公司爲聯邦聯合報稅團體的共同母公司的情況除外）。公司根據財政部法規第1.1502-6條（或任何類似的州、地方或外國法規）不存在對任何人的稅務責任，作爲受讓人或繼承人，或者根據合同（除了履行日常協議的情況）。

(i)公司未將他人的股票進行分配，或者未被他人進行股票分配，在交易中該交易據稱或意圖全部或部分受法典第355條或法典第361條的約束。

(j)公司尚未進行任何被視爲《財政部法規》第1.6011-4(b)(2)或第301.6111-2(b)(2)節所列交易。

(k)公司不知悉有關事實或情況，並且沒有采取或同意採取任何行動，無論哪種情況下，這些行動都不會合理地預計會阻止或妨礙預期的稅務處理。

3.17            員工和勞動事項; 福利計劃。

(a)公司已向母公司提供了一份（以匿名方式呈現）名單，列明每位公司員工（全職或兼職）的年薪（或按小時計算的時薪）、最近一次接受的年度獎金以及當前的年度獎金機會。沒有任何公司主要僱員向公司或其任何子公司表示由於本協議中擬議的交易或其他原因而打算辭職或退休。公司已向母公司提供了一份（以匿名方式呈現）名單，列明每位公司員工（爲公司僱員或其任何子公司員工）的年薪（或按小時計算的時薪）、最近一次接受的年度獎金以及當前的年度獎金機會。

(b)公司及其各附屬公司的僱員的僱傭關係可由公司和/或適用的附屬公司隨時終止。公司已向母公司提供準確完整的員工手冊副本，至今有效且重要。

(c)            公司及其任何子公司均不是任何集體談判協議或其他合同的一方，也沒有義務按照勞工組織代表其僱員的條款進行談判，也沒有任何代表公司員工的勞工組織，公司也沒有知悉有代表或試圖代表公司員工的勞工組織。

(d)            章節 ‎3.17(d)公司披露信函中列出的所有公司員工計劃（除了可以隨意終止的僱傭安排，公司或其任何子公司沒有任何合同義務要進行任何解僱、終止、控制變更或類似支付，並且在實質上與向母公司提供的僱傭安排相同）。

(e)每個公司員工計劃，旨在符合《法典》第401(a)節的資格，已收到IRS關於其合格地位的良好裁定或意見書。據公司所知，沒有發生任何可能會對任何這類公司員工計劃的合格地位或任何相關信託的免稅地位產生不利影響的事情。

(f)每一個公司員工計劃都在所有相關法律條款，包括但不限於《法典》、ERISA和《平價醫療法案》的規定下建立、維護和運營，保持充分合規。對於任何公司員工計劃，除了與日常福利索賠有關的外，沒有任何法律訴訟（公司知情的情況下）正在進行或威脅進行。根據適用公司員工計劃條款和適用法律的規定，所有應當支付的款項或貢獻已經支付或已經根據計提。

(g)公司或其任何ERISA關聯公司均不建立、貢獻，或有義務貢獻，或過去六（6）年內，建立、貢獻，或有義務貢獻過（i）任何受ERISA第四章或第302節，或稅收法第412節約束的「僱員福利計劃」，（ii）任何多僱主計劃，（iii）按照稅收法第419節涵義的任何資助福利計劃，（iv）任何多僱主計劃，或（v）任何多僱主福利安排。公司或其任何ERISA關聯公司從未在ERISA第四章下承擔任何責任。

(h)公司員工計劃不提供醫療或其他福利待遇給任何服務提供方，公司及其子公司也未承諾在服務終止或退休後向任何服務提供方提供醫療或其他福利待遇，除了（i）根據COBRA或類似州法規定或（ii）在服務終止或退休發生的月份結束時的續保計劃。公司未贊助或維持任何自助醫療或長期殘疾福利計劃。

(i)公司員工計劃不受美國境外任何外國司法管轄法律的約束。

(j)每個公司員工計劃在任何部分構成「非合格遞延補償計劃」（根據法典第409A(d)(1)條及其指導下定義的術語）（每個「 Company Employee Plan」）已在運營和文件上所有重大方面符合法典第409A條和適用指導的要求。公司409A計劃任何公司409A計劃實施或維護在所有重要方面都符合法典第409A條和適用指導的要求。在任何Company 409A計劃下支付的款項，或者按照Company 409A計劃的條款進行支付後，都不會受到法典第409A(a)(1)條的處罰。

(k)公司及其各附屬公司已經並且一直嚴格遵守所有適用的聯邦、州和地方法律、規則及法規，涉及就業、就業慣例、就業條件、員工分類、稅收代扣、禁止歧視、報復和騷擾、平等就業、公平就業慣例、餐食和休息時間、移民身份、員工和職場安全與健康、薪水（包括加班工資）、補償、工作時間、《工人調整和再培訓法》（1988年）或類似州或地方法律中「工廠停工」和「大規模裁員」的含義（“WARN法案”）、勞工慣例或糾紛、限制性條款、勞動合同、職工賠償及長期殘疾保險政策、休假以及員工隱私（統稱“與就業有關的法律”），就公司及其任何附屬公司的僱員而言：（i）已經依法或根據協議扣減並報告所有應扣減及報告的資料金額，包括工資、薪金及其他支付；（ii）不承擔任何工資拖欠、離職金或任何稅收或未能遵守前述任何事項所導致的任何重要金額的責任和懲罰；以及（iii）不需就與員工（除了例行業務中應支付的常規款項之外）的失業補償金、社會保險或其他待遇或義務有關的信託或其他由任何政府機關管理或維護的基金承擔任何重要付款責任。據公司知曉，沒有任何與僱員、臨時工、董事、僱傭合同或僱員計劃（除了定期權益索賠）或就業相關法律有關的任何重要法律訴訟、索賠、勞動糾紛、組織活動或者投訴正在進行中或有可能對公司或其任何子公司或公司的受託人或其任何附屬公司產生威脅或相對預期。據公司知曉，沒有任何正在進行中或可能對公司或公司的任何受託人或其任何附屬公司的受託人根據任何工傷保險政策或長期殘疾保險政策提起索賠或採取行動的重要索賠或訴訟。公司沒有參與一項與任何聯邦、州或地方機構或政府機關就就業慣例達成的和解協議、認可裁決或其他協議或訂單。

(l)公司在任何一家公司被錯誤分類（自公司成立以來）均無實質性責任：（i）將任何人作爲獨立承包商而非僱員進行分類，（ii）從其他僱主租用任何僱員，或（iii）目前或曾被分類爲免於加班工資的任何僱員。公司或其任何子公司均未採取任何構成《WARN法案》所定義的"工廠關閉"或"大規模裁員"的任何行動，也未發出《WARN法案》要求的任何工廠關閉或大規模裁員通知（也沒有公司或其任何子公司受到發出任何此類通知的要求或義務），亦未涉及或負擔任何尚未清償的《WARN法案》下的責任或義務。

(m)據公司所知，過去六個月內從未發生過任何罷工、放緩、工作停滯、停工、工作行動、工會、組織活動、有關代表問題或類似活動或爭議，並且目前也不存在任何可能直接或間接引發或提供開始此類罷工、放緩、工作停滯、停工、工作行動、工會組織活動、有關代表問題或類似活動或爭議的事件、狀況或情況。

(n)公司及其任何子公司未參與過任何重大不公平的勞動行爲，該不公平行爲的定義參照國家勞動關係法。公司沒有任何重大法律訴訟，申訴，勞資糾紛或投訴正在進行，或者據公司所知，威脅或可以合理預料的與任何員工合同，隱私權，勞資糾紛，工資和工時，休假，工廠閉廠通知，工人賠償政策，長期殘疾政策，騷擾，報復，移民，就業法規章，安全或歧視事項有關的。這些事項包括公司或其子公司的任何現任或前任僱員涉及的不公平勞動行爲指控或歧視投訴。

(o)公司或其任何子公司參與及受約束的合同、協議、計劃或安排均不包括爲了補償其員工或其他服務提供者根據《法典》支付的任何收入或消費稅，包括但不限於《法典》第4999或第409A節。

(p)            公司或其任何子公司均不是任何合同的一方，該合同的執行和交付以及本協議的股東批准，或本協議擬定的交易的完成，可能會導致（僅僅或與任何其他事件結合）使任何公司或其任何子公司的僱員、官員、董事或其他服務提供者的任何支付或福利的提前獲得、支付、資金撥付或交付，或增加任何支付或福利的金額或價值。

3.18            環保母基 事項公司已經遵守了所有適用的環保法律，這包括公司擁有根據適用環保法律所需的所有許可證和其他政府授權，並遵守其中的條款和條件，除非存在不符合規定的情況，即使單獨或合計起來也不會導致公司出現重大不利影響。公司沒有收到任何書面通知或其他通信（無論書面還是其他形式的），無論是來自政府機構、公民團體、員工還是其他人，都沒有聲稱公司不符合任何環保法律的要求，並且據公司所知，沒有任何情況可能阻止或干擾公司未來遵守任何環保法律的能力，除非這種不符合規定不會合理地預期會對公司產生重大不利影響。據公司所知：（i）任何由公司租賃或控制的物業的當前或以前的所有者都沒有收到任何書面通知或其他關於公司在任何時候擁有所有或租賃的物業的、無論是來自政府機構、公民團體、員工還是其他人的涉及聲稱該當前或以前的所有者或公司不符合或違反了與該物業相關的任何環保法律的聲稱；和（ii）公司在任何環保法律下沒有重大責任。公司已經提供了所有與其業務和當前或以前設施相關的環境現場評估、環境審計和其他重要環境文件，這些文件位於公司的掌握或控制之中。

3.19            保險公司已向母公司提供了所有與公司業務、資產、負債和業務有關的重要保險政策以及所有重要的自保計劃和安排的準確完整副本。這些保險政策均有效且公司在所有重大方面均遵守其條款。除了保險承運人的例行保單到期通知外，公司沒有收到任何關於任何實際或可能的:(i)保險單的取消或無效化或(ii) 拒絕或否定任何保險範圍、保留權或拒絕任何保險單項索賠的通知或其他通信。公司已及時向適當的保險承運人書面通知了針對公司的每項司法程序，沒有任何保險承運人就任何此類司法程序發佈拒絕承保或保留權，或通知公司其打算這樣做。

3.20            沒有 理財顧問除《基本報表》上所述之外，公司在交易中未僱用任何經紀人或中介。 公司披露函第3.20節 根據公司或代表公司安排的安排，沒有券商、查找器或投資銀行家有權一切券商費用、查找費、意見費、成功費、交易費或其他費用或佣金與考慮中的交易有關。

3.21            與關聯方的交易 . 第3.21節 公司披露函的第 項描述了公司與公司的執行官或董事、該執行官或董事的直系家庭成員、持有公司表決權超過 5% 的股東或據公司了解，該公司執行官、董事或股東（公司除外）的「關聯人」（在《證券法》下S-k條規404項的涵義內）之間的任何重要交易或關係，對於（a）、（b）或（c）中的每一種情況，如果是屬於根據《證券法》下S-k條規404項要求披露的類型，則須予披露。

3.22            隱私 和數據安全。公司一直遵守所有適用的隱私法和適用條款 有關隱私、數據保護、數據安全、跨境數據流、數據丟失、數據盜竊或泄露的任何公司合同 通知、數據本地化、發送請求或未經請求的電子郵件或短信、Cookie 或其他跟蹤技術， 或收集、處理、使用、維護、存儲、披露、轉移或以其他方式處理個人信息（包括 個人、臨床試驗參與者、患者、患者家屬、護理人員或倡導者、醫生的任何此類信息 以及其他與公司互動的醫療保健專業人員、臨床試驗研究人員、研究人員、藥劑師 與公司業務的運營有關），除非在任何情況下都沒有違規行爲，也不會合理地 預計將單獨或總體上對公司產生重大不利影響。據公司所知，公司 (i) 已實施並維持合理的書面政策和程序，這些政策和程序實質上符合適用的隱私法 並旨在保護個人信息的隱私和安全（”隱私政策”) 和 (ii) 有 遵守了此類隱私政策，但個人過去和合理預期不會遵守的違規行爲除外 或總體而言，是公司的重大不利影響。據公司所知，沒有人提起或威脅提起任何法律訴訟 任何人指控違反隱私法、隱私政策或任何公司合同的適用條款，對公司提起訴訟 管理隱私、數據保護、數據安全、跨境數據流、數據丟失、數據盜竊或泄露通知、數據本地化， 發送未經請求或未經請求的電子郵件或短信、Cookie 或其他跟蹤技術，或收集、處理、 個人信息的使用、維護、存儲、披露、轉移或其他處理。據公司所知，有 沒有發生任何數據安全事件或數據泄露或其他不利事件或導致任何未經授權訪問的事件， 使用、披露、修改或銷燬本公司或任何人擁有或控制的個人信息或其他數據 在每次此類事件、違規或事件導致通知義務的情況下，代表公司行事的服務提供商 根據適用法律或任何公司合同的條款，向任何人披露。

3.23            母公司資本股份的所有權。 公司、其董事或據公司所知，公司的任何高級職員、關聯公司或公司的任何受控關聯公司的員工（a）在此前三年內未曾擁有過母公司的任何股份；或（ b）在此前三年內未曾是母公司的「利害關係股東」（根據DGCL第203條的定義），無論哪種情況。

3.24            無 其他陳述或保證公司特此承認並同意，除本協議中包含的陳述和保證外，母公司或母公司代表的其他任何人並未就母公司或與母公司有關的任何其他信息，或就本次交易所涉任何相關方的部分股東或其各自的關聯方向公司提供的任何信息，作出明示或默示的陳述或保證，且（受限於母公司披露信函中明示的陳述和保證）母公司，公司或任何其代表或股東，並未依賴任何此類信息（包括其準確性或完整性）。 第 4 （在母公司披露函中的相應限制和限定條件）公司或其代表或股東並沒有依賴任何此類信息（包括其準確性或完整性）。

公司不得，也不得允許其任何受限制附屬公司與任何主要財產有關的進行出售/租回交易，除非（a）公司或受限制附屬公司有權在不按照本補充契約第4條的規定爲2028年債券提供擔保的情況下創建抵押權 在銷售/租回交易中，該主要財產的抵押債務等於有關銷售/租回交易的屬性債務；或者（b）公司在銷售/租回交易的生效日期之內的六個月內，申請自願解除或退休 有關2028年債券或與2028年債券排名相同的其他債務（不包括由於轉換或根據到期日強制性沉沒基金或強制性預付款條款或按到期日支付而退休）相當於該銷售/經營租賃交易中有關的負債。上述情況不會阻止公司或任何受限制附屬公司（x）進行任何租期不超過三年的出售/回租交易，或（y）進行任何受限制附屬公司之間或公司與受限制附屬公司之間的出售/回租交易。母公司、第一次合併和第二次合併子公司的陳述和保證.

除了（i）如家長公司交付給公司的書面披露文件中所述以外，（母公司披露函）與簽署本協議同時發送的或（ii）在此日期之前向SEC提交的家長公司SEC文件中披露的並且在SEC電子數據收集分析和檢索系統中公開可得（但（A）不考慮在此日期之後向SEC提交的或提供給SEC的任何修正案，和（B）不包括任何披露在「風險因素」標題下或在任何其他部分中的風險披露，只要它們是前瞻性聲明或警示性、預測性或前瞻性的性質），應理解爲家長公司SEC文件中披露的任何事項應被視爲在《家長披露信函》的一個部分中披露，只要從閱讀家長公司SEC文件中是顯而易見的，這些事項適用於《家長披露信函》的該部分或子部分，家長公司、第一合併子公司和第二合併子公司向公司陳述並保證如下：

4.1            由 組織; 子公司.

(a)父公司、第一合併子公司和第二合併子公司均爲依法成立或組建的公司，根據各自的組建或成立管轄權下的法律，合法存在並且保持良好的地位，並具有一切必要的公司權力和權威：（i）以目前業務所採取的方式開展業務；（ii）以目前所有屬性和資產所擁有或租賃和使用的方式擁有或租賃和使用其財產和資產；以及（iii）履行其受約束的所有合同下的義務。自成立以來，合併子公司未從事與本協議有關或本協議所預期的活動之外的任何活動。

(b)每個母公司及其子公司均具備經營許可並有權經營，在其業務性質和當前經營方式所要求的所有司法管轄區的法律下具備符合資格，並非在可能會導致母公司重大不利影響的司法管轄區以外未取得相關許可或資格。

(c)除Merger Sub外，母公司沒有其他子公司，也沒有除設置在披露信函的以外的任何附屬公司。 第4.1(c)節在母公司披露信函的 一節，母公司不擁有任何母公司的股票，或任何其他實體的股權或利潤分享權益，也不直接或間接地控制其他實體，除Merger Sub外。除披露信函的 一節所設置的以外。 第4.1(c)節在母公司披露信函的 一節 之外，母公司不是，也從未直接或間接地是，任何合夥企業，合資企業或類似業務實體的一方，也不是合夥企業，合資企業或其他實體的成員或參與方。母公司沒有同意也不受約束要進行，也不受任何協議約束要進行，也不受任何協議約束要進行，也不受任何協議約束要進行，也不受任何協議約束要進行，也沒有義務進行向任何其它實體的未來投資或資本貢獻。母公司在任何時候都不是任何一家普通合夥企業的普通合夥人，也不對任何普通合夥企業，有限合夥企業或其他實體的任何債務或其他責任承擔任何責任。

4.2            組織文件公司的公司文件的副本準確無誤地交付給公司。母公司在任何重大方面都沒有違反或違反其公司文件。

4.3            權威性； 協議的約束力母公司和每個合併子公司具有簽訂並履行本協議項下的義務以及完成所述交易的必要公司權力及權威。母公司董事會已經： (a)確定所述交易對母公司及其股東是公平的、明智的，並且符合母公司及其股東的最佳利益， (b)批准並認爲本協議和所述交易是明智的，包括根據本協議向公司股東發行母公司股本股份， (c)確定在本協議規定的條件下，根據所述交易推薦母公司股東投票批准所述交易，並且如母公司和公司認爲必要時，由母公司及公司根據本協議的條款就(1)將母公司更名爲「Crescent Biopharma, Inc.」、(2)實施納斯達克逆向拆分以及(3)進行其他雙方同意的變更的公司章程修正進行表決。第一合併子公司董事會（通過全體一致書面同意）已經： (x)確定所述交易對第一合併子公司及其唯一股東是公平的、明智的，並且符合最佳利益， (y)認爲並批准本協議和所述交易是明智的，並且(z)確定在本協議規定的條款下推薦第一合併子公司股東投票通過本協議並因此批准所述交易。第二合併子公司唯一成員（通過全體一致書面同意）已經： (A)確定所述交易對第二合併子公司及唯一成員是公平的、明智的，並且符合最佳利益；並且(B)認爲並批准本協議和所述交易。本協議已由母公司和合並子公司妥善簽署並交付，假定公司已根據 第3.23節在法律上，構成對母公司和合並子公司履行其義務的合法、有效且具約束力，在符合條款的情況下，受可強制實施例外情況的限制。

4.4            所需表決。假設在這個章節的表述準確無誤 第3.23節，在母公司股東大會上，只需獲得母公司普通股股東中正確投票的多數股份即可批准本協議，從而批准擬議交易和「母公司章程修訂」定義中的(i)、(ii)和(iii)條款（統稱爲“所需的母公司股東投票”).

4.5            非違反； 同意.

(a)在獲得要求的大股東投票、符合適用的HSR法案要求（如果適用）和提交DGCL或DLLCA要求的合併證書和指定證明書，並假設陳述的準確性。 章節 ‎3.23，無論是(x) 父公司或合併公司簽署、交付或履行本協議，還是(y) 完成擬議交易，都不會直接或間接（有或沒有通知或經過時間）：

(i)違反， 與父公司或其子公司的組織文件的任何規定發生衝突或導致違反；

(ii)違背、與之衝突或導致對父公司或其子公司擁有或使用的資產受制於的任何法律或法院裁決提出質疑或授予任何行政機關或其他個人挑戰所考慮的交易或行使任何補救措施或獲得任何救濟的權利。

(iii)違反，與父類或其子公司持有或與父類業務有關的任何政府授權相關的條款或要求，或使任何政府機構有權撤銷、撤回、暫停、取消、終止或修改父類或其子公司持有的任何政府授權，或與父類擁有、租賃或使用的任何資產相關。

(iv)違背，與或導致違反或違約，或導致任何母公司物資合同的任何條款下發生違約，使任何人有權：(A)宣佈違約或在任何母公司物資合同下行使任何救濟措施，(B)任何實質支付，回扣，退款，處罰或交貨時間表變更，(C)加速任何母公司物資合同的到期或履行或(D)取消，終止或修改任何母公司物資合同的任何條款，但在任何非實質性違約，違約，罰款或修改的情況下除外；或

(v)在對母公司或其子公司擁有或使用的任何資產施加或設立任何負擔（除非爲允許負擔）時的結果。

(b)除非（i）在任何母公司合同的母公司披露函中的任何同意書， （ii）必要的母公司股東投票， （iii）根據DGCL或DLLCA向特拉華州國務卿提交合並證書和指定證書，（iv）遵守HSR法案（如適用）的任何適用要求，以及（v）根據適用的聯邦和州證券法律可能需要的同意，豁免，批准，訂單，授權，登記，聲明和申報，且假定在...的陳述準確無誤的情況下，除非父母或其子公司是，或將被要求與，任何人進行任何提交或向，獲得任何...的通知... 章節 ‎4.5(a)母公司或其任何子公司未，未或將被要求與任何人聯繫，在執行、交付或執行本協議，或思考交易的完成... 章節 ‎3.23每個部分或每個部件都是完整的，並保留原有的語法組織，以確保譯文與原文的對應關係...請仔細閱讀逐字翻譯的文本，以便準確理解文本的含義...

(c)假設 表示法的準確性 部分‎3.23，母公司委員會和第一合併分委員會已經採取了 並將採取一切必要行動，確保第203節中適用於企業合併的限制 DGCL 現在和將來都不適用於本協議的執行、交付和履行以及本協議的完成 預期的交易。沒有其他州收購法規或類似法律適用於或聲稱適用於本協議的合併 或任何其他預期的交易。

4.6            資本化 .

(a)母公司的授權股本包括（i）母公司普通股150,000,000股，其中截至2024年9月30日已發行並流通的股份爲64,483,958股（“資本化日期”），以及（ii）母公司優先股5,000,000股，每股面值$0.001，但尚未指定。母公司在資本化日期時未發行或流通任何股份優先股。母公司不持有任何股份作爲其資本庫存。

(b)所有板塊的優先普通股已經得到適當授權並已經有效發行，並且全部已支付且免責，並且沒有任何除組織文件或適用證券法規定的以外的擔保權，沒有任何的優先普通股享有或受到任何優先購買權、參與權、維持權或類似權利，且沒有任何優先普通股受到任何優先購買權的限制。除本文所述外，不存在任何關於投票或註冊的父公司合同，也沒有任何限制任何人購買、出售、質押或以其他方式處置（或授予任何關於）父公司優先普通股的合同。母公司沒有義務，也不受任何合同約束，根據該合同，可能要求其購回、贖回或以其他方式收回任何未償還的母公司優先普通股或其他證券。 章節 ‎4.6(b)母公司披露函準確完整地描述了母公司所持有的有關母公司優先普通股的回購權利（包括根據行權期權發行的股份）並指明瞭其中哪些回購權目前可行使。

(c)除了 適用於母公司2003年股票激勵計劃、母公司2013年股權激勵計劃和2020年母公司激勵計劃（均可能修訂） 不時集體地，”母股計劃”），除非另有規定 部分‎4.6(c)的 母公司披露信，母公司沒有任何股票期權計劃或任何其他計劃、計劃、協議或安排提供 爲任何人提供任何基於股權的薪酬。截至資本化日，母公司已預留14,257,627股母公司普通股 根據母公司股票計劃發行的股票，其中13,163,469股已發行且目前正在流通，爲117,157股 已預留用於在行使或結算母公司期權和母公司限制性股票單位（如適用）時發行 根據母股計劃，根據母股計劃，仍有977,001股股票可供未來發行。截至資本化 日期，母公司已根據母公司ESPP預留了3,554,364股母公司普通股供未來發行（其中0股） 已發行，目前尚未發行）。 部分‎4.6(c)《家長披露信》中規定 有關截至資本化日未償還的每份母公司期權的以下信息（如適用）：(i) 名稱 持有人的，(ii) 受此類母公司期權和母公司限制性股票單位約束的母公司普通股的數量 截至資本化日，(iii) 該母公司期權的行使價，(iv) 該母公司期權的行使價，(iv) 該母公司期權的日期或 母公司限制性股票單位獲得批准，(v) 適用的歸屬時間表，包括任何加速條款，(vi) 此類母公司期權的到期日期，（vii）該母公司期權是否打算成爲 「激勵性股票期權」 （定義見守則）或不合格股票期權以及（viii）就母公司期權而言，該計劃所依據的計劃 家長期權已獲授權。母公司已根據以下規定向公司提供了股權激勵計劃的準確而完整的副本 哪家母公司擁有股權獎勵、證明此類股權獎勵的所有獎勵協議的形式以及董事會證據，以及 股東批准母股計劃及其任何修正案。

(d)除了優秀的母公司期權和母公司限制性股票單位外，或如所述於 章節 ‎4.6(d)母公司披露信函的圖 沒有：(i) 未行使的訂閱，期權，看漲，認股權證或權利（無論當前是否可以行使）以取得母公司的任何股票或其他證券，（ii） 未行使的證券，工具或可轉換爲或可交換爲母公司股票或其他證券的義務，（iii） 股東權益計劃（或通常稱爲"毒丸"的類似計劃）或根據該計劃可能被迫出售或以其他方式發行其任何股票或任何其他證券或（iv） 可能引發或提供依據主張的條件或環境任何人可以獲得或接收任何母公司股票或其他證券的權利。 母公司沒有與其相關的未行使或已授權的股票增值權，虛擬股票，利潤分享或其他類似權利。

(e)所有板塊的母公司普通股、母公司期權、母公司限制性股票單位和其他證券均已按照（i）所有適用的證券法律和其他適用法律以及（ii）適用合同中規定的所有要求的原則，發行和授予。

(f)就父母期權和父母受限股票單位而言，根據父母股票計劃授予的每一份父母期權或父母受限股票單位均於其規定生效日期之前經過必要的公司授權，包括但不限於父母董事會（或其正式組成的授權委員會）或正式授權的管理人員的批准，以及股東按必要票數批准或書面同意（如適用），每一份父母期權和父母受限股票單位授予均按照授予該期權的父母股票計劃以及所有其他適用的法律和監管規則或要求進行，每一份父母期權的每股行使價格均不低於適用父母授予日期的一股父母普通股的公允市場價。母公司授予日期就父母期權和父母受限股票單位而言，根據父母股票計劃授予的每一份父母期權或父母受限股票單位均於其規定生效日期之前經過必要的公司授權，包括但不限於父母董事會（或其正式組成的授權委員會）或正式授權的管理人員的批准，以及股東按必要票數批准或書面同意（如適用），每一份父母期權和父母受限股票單位授予均按照授予該期權的父母股票計劃以及所有其他適用的法律和監管規則或要求進行，每一份父母期權的每股行使價格均不低於適用父母授予日期的一股父母普通股的公允市場價。

4.7            SEC 文件；基本報表.

(a)父公司已準時提交或提交了所有必須向交易所委託或向證券交易委員會提交的所有表單、聲明、認證、報告和文件（以下簡稱「公司委託」）。母公司SEC文件截至提交給證券交易委員會的時間（或者，如果被本協議簽署日期之前的某個日期前修正或取代的聲明，那麼是在該提交日期），每份公司委託在所有重大方面符合證券法或交易所法規的要求，同時在提交時，沒有一份公司委託包含任何重大事實的不實陳述或遺漏在其中需陳述的重要事實或爲了使其陳述不具有誤導性的必要事實。要求（i）根據交易法案第13a-14條和（ii）18 U.S.C. §1350（薩班斯-奧克斯利法案第906條）而需要的針對公司委託的認證和聲明（合稱「公司認證」）準確完整，並在形式和內容上符合所有適用法律規定。在本文中的使用，「提交」一詞及其各種變種應被廣泛解釋，包括向證券交易委員會提交文件或信息的任何方式。認證豪利公司文件 章節 ‎4.7在這個文件中，「提交」一詞及其變種應被廣泛解釋，包括以任何方式向證券交易委員會提供文件或信息的任何方式。

(b)包含在或通過參考上市公司SEC文件中的財務報表（包括任何相關附註）：(i) 在形式上在所有重大方面符合證券法和《交易法》，適用的SEC規則和法規，並且（ii）按照通用會計準則編制（除非在這些財務報表的附註中註明，或者在未經審計的財務報表的情況下，根據SEC的10-Q表允許，並且未經審計的財務報表可能不包含腳註，並且受到正常和經常性年終調整的影響，這些調整不應該預計會影響金額不大），除非在上述期間指定的情況下在一致基礎上應用，（iii）在所有重大方面公正地表述了上市公司於相應日期的財務狀況，以及爲所涵蓋期間的業務結果和現金流量。除非在此前提交給SEC的公司文件中明確披露，否則母公司的會計方法或原則未發生重大變化，這些變化需要根據通用會計準則披露在母公司的財務報表中。母公司及其各附屬公司的賬簿和其他財務記錄在所有重大方面均真實完整。

(c)            Parent’s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, “independent” with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.

(d)            Except as set forth on Section ‎4.7(d) of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.

(e)            There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.

(f)            Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq.

(g)            Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent’s transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent’s assets that could have a material effect on Parent’s financial statements. Parent has evaluated the effectiveness of Parent’s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent’s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent’s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent’s or its Subsidiaries’ internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent’s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent’s internal control over financial reporting.

(h)            Parent’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent’s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

4.8            Absence of Changes. Except as set forth on Section ‎4.8 of the Parent Disclosure Letter, between December 31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to Section ‎Section 5‎(b) of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.

4.9            Absence of Undisclosed Liabilities. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Contemplated Transactions or the Subscription Agreement, and (e) Liabilities described in Section ‎4.9 of the Parent Disclosure Letter.

4.10            Title to Assets. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Parent Balance Sheet and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.

4.11            Real Property; Leasehold. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list of all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b) copies of all leases under which any such real property is possessed (the “Parent Real Estate Leases”), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent’s Knowledge, the other party thereto.

4.12            Intellectual Property.

(a)            Section ‎4.12(a) of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.

(b)            Section ‎4.12(b) of the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent’s standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.

(c)            Section ‎4.12(c) of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent’s benefit).

(d)            Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.

(e)            Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent IP Rights licensed to Parent, or co-owned rights each as identified in Section ‎4.12(e) of the Parent Disclosure Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries’ products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:

(i)            All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.

(ii)           Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.

(iii)          To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.

(iv)          No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.

(v)           Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.

(vi)          Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.

(f)            Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.

(g)            The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.

(h)            As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.

(i)            To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.

(j)            Except as may be set forth in the Contracts listed on Section ‎4.12(b), ‎4.12(c) or ‎4.12(k) of the Parent Disclosure Letter or as contained in “off-the-shelf” license agreements entered into in the Ordinary Course of Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.

(k)            Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.

4.13            Agreements, Contracts and Commitments.

(a)            Section ‎4.13 of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement other than the Subscription Agreement (each, an “Parent Material Contract” and collectively, the “Parent Material Contracts”):

(i)            each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;

(ii)           each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days’ or less notice without liability;

(iii)          each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;

(iv)          each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;

(v)           each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent’s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;

(vi)          each Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;

(vii)         each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;

(viii)        each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;

(ix)          each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;

(x)           each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;

(xi)          each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;

(xii)         each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;

(xiii)        each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;

(xiv)        each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;

(xv)         any Parent Real Estate Lease;

(xvi)        a Contract disclosed in or required to be disclosed in Section ‎4.12(b) or Section ‎4.12(c) of the Parent Disclosure Letter; or

(xvii)       any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken as a whole.

(b)            Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent’s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.

4.14            Compliance; Permits; Restrictions.

(a)            Parent and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent’s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.

(b)            Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the “Parent Permits”). Section ‎4.14(b) of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.

(c)            There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.

(d)            Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the “Parent Product Candidates”) (the “Parent Regulatory Permits”) and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner other than immaterial adverse modifications. Section ‎4.14(d) of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent’s or its Subsidiaries’ possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.

(e)            All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.

(f)            Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA’s “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section 335a or (ii) any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.

(g)            All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA’s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.

(h)            None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.

4.15            Legal Proceedings; Orders.

(a)            There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.

(b)            There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.

4.16            Tax Matters.

(a)            Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.

(b)            All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).

(c)            Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.

(d)            There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a) of the definition of “Permitted Encumbrances”) upon any of the assets of Parent or any of its Subsidiaries.

(e)            No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.

(f)            Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.

(g)            Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).

(h)            Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code.

(i)            Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a “listed transaction” for purposes of Treasury Regulations Sections 1.6011-4(b)(2) or 301.6111-2(b)(2).

(j)            Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.

4.17            Employee and Labor Matters; Benefit Plans.

(a)            The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee’s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor’s name, duties and rate of compensation.

(b)            The employment of Parent’s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.

(c)            Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.

(d)            Section ‎4.17(d) of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable “at will” without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).

(e)            Each Parent Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.

(f)            Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.

(g)            Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any “employee benefit plan” that is or was subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section 419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.

(h)            No Parent Employee Plan provides for, and neither Parent nor any of its Subsidiaries has promised to provide any, medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i) pursuant to COBRA or an analogous state law requirement or (ii) continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.

(i)            No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.

(j)            Each Parent Employee Plan that constitutes in any part a “nonqualified deferred compensation plan” (as such term is defined under Section 409A(d)(1) of the Code and the guidance thereunder) (each, a “Parent 409A Plan”) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section 409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section 409A(a)(1) of the Code.

(k)            Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i) has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii) is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii) is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers’ compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.

(l)            Parent has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a “plant closing” or “mass layoff” within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.

(m)            To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.

(n)            Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers’ compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.

(o)            There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section 4999 or Section 409A of the Code.

(p)            Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) (i) result in the payment of any “parachute payment” within the meaning of Section 280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.

4.18            Environmental Matters. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent’s or any of its Subsidiaries’ compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent’s possession or control relating to the Parent and its Subsidiaries, including the Parent’s and its Subsidiaries’ business and current or former facilities.

4.19            Insurance. Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.

4.20            Transactions with Affiliates. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent’s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. Section ‎4.20 of the Parent Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.

4.21            No Financial Advisors. Except as set forth on Section ‎4.21 of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.

4.22            Valid Issuance. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion thereof) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of any Parent Capital Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.

4.23            Privacy and Data Security. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent’s and its Subsidiaries’ business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.

4.24            No Other Representations or Warranties. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in Section 3 (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).

Section 5. Certain Covenants of the Parties.

5.1            Operation of Parent’s Business.

(a)            Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii) as set forth in Section ‎5.1(a) of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 10 and the First Effective Time (the “Pre-Closing Period”), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.

(b)            Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii) as set forth in Section ‎5.1(b) of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:

(i)            declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);

(ii)           except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;

(iii)          sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;

(iv)          form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;

(v)           (A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others or (D) make any capital expenditure or commitment in excess of $25,000;

(vi)          (A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section 409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D) increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E) hire any officer, employee or consultant;

(vii)         acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;

(viii)        sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);

(ix)          other than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;

(x)           waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;

(xi)          delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;

(xii)         forgive any loans to any Person, including its employees, officers, directors or Affiliate;

(xiii)        terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;

(xiv)        (A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;

(xv)         enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or

(xvi)        agree, resolve or commit to do any of the foregoing.

Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.

5.2            Operation of the Company’s Business.

(a)            Except (i) as expressly contemplated or permitted by this Agreement, (ii) as set forth in Section ‎5.2(a) of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to any Interim Financing or Company Acquisition, which are expressly permitted, or (v) unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.

(b)            Except (i) as expressly contemplated or permitted by this Agreement, (ii) as set forth in Section ‎5.2(b) of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) in connection with any Interim Financing or Company Acquisition, which are expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:

(i)            declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);

(ii)           except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries’ Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;

(iii)          other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;

(iv)          other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;

(v)           (A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;

(vi)          sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;

(vii)         sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);

(viii)        waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;

(ix)           enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or

(x)            agree, resolve or commit to do any of the foregoing.

Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.

5.3            Access and Investigation.

(a)            Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party’s Representatives to: (a) provide the other Party and such other Party’s Representatives with reasonable access during normal business hours to such Party’s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b) provide the other Party and such other Party’s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c) permit the other Party’s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party’s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this Section ‎5.3 shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.

(b)            Notwithstanding anything herein to the contrary in this Section ‎5.3, no access or examination contemplated by this Section ‎5.3 shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; provided, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.

5.4            No Solicitation.

(a)            Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly,: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii) furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v) publicly propose to do any of the foregoing; provided, however, that, (x) any public disclosures made in compliance with Section 6.3(e) shall not constitute a violation of this Section 5.4 and (y) notwithstanding anything contained in this Section ‎5.4 and subject to compliance with this Section ‎5.4, prior to the approval of this Agreement by a Party’s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party’s board of directors determines in good faith, after consultation with such Party’s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors’ fiduciary duties under applicable Law, (C) at least two (2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party’s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E) at least two (2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this Section ‎5.4 by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this Section ‎5.4 by such Party for purposes of this Agreement.

(b)            If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one (1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.

(c)            Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.

(d)            For the avoidance of doubt and notwithstanding anything to the contrary in this Section ‎5.4, the Company shall be expressly permitted to take any action with respect to an Interim Financing or a Company Acquisition.

5.5            Notification of Certain Matters. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b) any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in ‎6.19, Section 8 or Section 9, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x) determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y) determining whether any condition set forth in ‎6.19, Section 8 or Section 9 has been satisfied. Any failure by either Party to provide notice pursuant to this Section ‎5.5 shall not be deemed to be a breach for purposes of Section ‎8.2 or Section ‎9.2, as applicable, unless such failure to provide such notice was knowing and intentional.

Section 6. Additional Agreements of the Parties.

6.1            Proxy Statement.

(a)            On or prior to February 14, 2025, Parent shall prepare and file with the SEC a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Parent Stockholder Matters (together with any amendments thereof or supplements thereto, the “Proxy Statement”). Parent shall use its commercially reasonable efforts to (i) cause the Proxy Statement to comply with applicable rules and regulations promulgated by the SEC and (ii) respond promptly to any comments or requests of the SEC or its staff related to the Proxy Statement.

(b)            Parent covenants and agrees that the Proxy Statement (and the letters to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities Laws and the DGCL, and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

(c)家長應盡商業上合理的努力，確保在代理聲明已提交給SEC後，儘快將其郵寄給家長的股東， 當滿足以下任一條件時：(i) SEC已表示不打算審核代理聲明，或已完成對代理聲明的審核， 或(ii) 自代理聲明提交給SEC後，至少有十（10）天過去，而未收到SEC對代理聲明進行評論或表示 其打算審核代理聲明的任何函件，所有這些均符合適用的美國聯邦證券法和DGCL。如果家長、第一次合併子公司、第二次合併子公司或存續實體（1）意識到根據證券法或 交易法應在代理聲明的修正案或補充中披露的任何事件或信息，(2) 收到SEC關於代理聲明修正案或補充 或相關額外信息的請求通知，或(3) 收到SEC對代理聲明的評論，視情況而定，那麼該方在這種情況下應 及時通知其他方，並與其他方合作，促使家長向SEC提交該修正案或補充，並在適當情況下向家長 股東郵寄該修正案或補充。公司及其法律顧問應有合理的機會在向SEC提交代理聲明及其所有修正和補充之前進行審查和 評論，並在回應SEC對代理聲明的任何評論之前對其進行審查。家長可以在未獲得公司的事先同意的情況下 提交代理聲明或任何修正或補充。

(d)在合理可行的情況下，公司將在2024年12月31日之後儘快向母公司提供截至2024年12月31日的經審計基本報表（即“公司基本報表”）要求在代理聲明中包含。

6.2            公司 股東書面同意.

(a)立即 在本協議發佈之日之後，無論如何不遲於其後的兩 (2) 個工作日，公司應獲得以下人員的批准 公司股東的書面同意，足以根據第 228 條進行必要的公司股東投票以代替會議 DGCL，目的是 (i) 通過和批准本協議和預期交易，(ii) 確認 由此獲得的批准是不可撤銷的，並且該股東知道根據其有權要求對其股票進行評估 至DGCL第262條，該股東已收到並閱讀了DGCL第262條的副本，以及（iii）確認 通過批准合併，它無權獲得與合併有關的股份的評估權，以及 因此，放棄了根據DGCL獲得其股本公允價值付款的任何權利（”公司股東 書面同意”）。在任何情況下，公司均不得斷言其需要任何其他批准或同意 股東批准本協議和預期交易。

(b)合理地 在收到所需的公司股東投票後，公司應準備並郵寄通知（“股東通知）給每位未簽署公司股東書面同意的股東。股東通知應（i）陳述公司董事會根據DGCL第251(b)條的規定，認爲合併是可行的，並符合公司股東的最佳利益，並批准和採納本協議、合併及其他預期交易，（ii）向收到通知的公司股東提供有關公司股東書面同意中採取的行動的通知，包括根據DGCL第228(e)條以及公司的章程和細則批准和採納本協議、合併及其他預期交易的通知，（iii）包括對公司股東在DGCL下可獲得的評估權利的描述，以及根據適用法律所要求的其他信息。所有提交給公司股東的材料（包括任何修訂）均須遵循本 第‎6.2(b)條應接受母公司的事先審核和合理批准。

(c)公司同意，受限於 第‎6.2(d)(i) 公司董事會應建議公司的股東投票通過本協議及相關交易，並應在 第‎6.2(a)（公司董事會建議公司股東投票通過本協議的稱爲“公司董事會推薦”) 及 (ii) 公司董事會建議不得以不利於母公司的方式被撤回或修改（公司董事會不得公開提議撤回或修改公司董事會建議），且公司董事會或其任何委員會不得通過或提議以不利於母公司的方式撤回或修改公司董事會建議，或採納、批准或推薦（或公開提議採納、批准或推薦）任何收購提案。

(d)            Notwithstanding anything to the contrary contained in Section ‎6.2(c), and subject to compliance with Section ‎5.4 and Section ‎6.2, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a “Company Intervening Event”), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a “Company Board Adverse Recommendation Change”) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if, Parent has delivered to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (1) Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four (4) Business Days in advance of the Company Board Adverse Recommendation Change (the “Notice Period”), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company’s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this Section ‎6.2(d) and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.

(e)            The Company’s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with Section ‎6.2(a) shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.

6.3            Parent Stockholder Meeting.

(a)            Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve (I) the issuance of shares of Parent Capital Stock (including shares of Parent Capital Stock issuable upon conversion thereof) in connection with the Contemplated Transactions for purposes of the listing rules of Nasdaq, and (II) the Parent Charter Amendment (collectively, the “Parent Stockholder Matters” and such meeting, the “Parent Stockholder Meeting”). The Parent Stockholder Meeting shall be held as promptly as practicable after the filing of the Proxy Statements in accordance with Section ‎6.1(a), and in any event, no later than 60 days after the date thereof. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.

(b)            Parent agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in Section ‎6.3(a) above and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent’s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the “Parent Board Recommendation”).

(c)            Notwithstanding anything to the contrary contained in Section ‎6.3(b), and subject to compliance with Section ‎5.4 and Section ‎6.3, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company (a “Parent Board Adverse Recommendation Change”) if, at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, or (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a “Parent Intervening Event”), if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (1) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance of the Parent Board Adverse Recommendation Change (the “Parent Notice Period”), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent’s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this Section ‎6.3(c) and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.

(d)            Parent’s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with Section ‎6.3(a) shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.

(e)            Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules 14d-9 and 14e-2(a) promulgated under the Exchange Act; provided, however, that any disclosure made by Parent or the Parent Board pursuant to Rules 14d-9 and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder’s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of Regulation M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in Section 5.4; or (iv) making any disclosure that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law or by any listing or trading rules or regulations of Nasdaq; provided that, in the case of (iv), Parent shall provide the Company with a reasonable opportunity to review any such disclosure not less than two (2) Business Days prior to the making thereof (or, if two Business Days is not reasonably practicable under the circumstances, such shorter period of time as is reasonably practicable under the circumstances) and shall consider in good faith any comments from the Company thereto.

6.4            Efforts; Regulatory Approvals.

(a)            The Parties shall use commercially reasonable efforts to obtain all regulatory approvals required by applicable Law to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv) shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.

(b)            Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.

(c)            Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (“Transaction Litigation”) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; provided that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely affect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good faith the Company’s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.

6.5            Company Options; Company Warrants.

(a)            At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option (including any Service Provider Grants), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an “Assumed Option”), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B) the Exchange Ratio; provided, that in the case of any Company Option to which Section 421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section 422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section 424(a) of the Code; provided further, that in the case of any Assumed Option to which Section 409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section 409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.

(b)            At the First Effective Time, each Company Warrant, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an “Assumed Warrant”), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii) the Exchange Ratio (rounded up to the next whole share of Parent Common Stock to the extent the aggregate amount of fractional shares of Parent Common Stock such holder of Assumed Warrants would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down), and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.

6.6            Employee Benefits.

(a)            Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on Section ‎4.17(d) or contemplated by Section ‎5.1(b) of the Parent Disclosure Letter, subject to the provisions of such agreements. The parties acknowledge and agree that the Merger shall not constitute a “change in control” (or term of similar import) under any Company Employee Plan.

(b)            From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an “employee welfare benefit plan” as defined in Section 3(1) of ERISA (each, a “Post-Closing Welfare Plan”) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.

(c)            Parent 401(k) Plan. Unless directed otherwise by the Company in writing no less than three (3) Business Days before the Closing Date, Parent shall, at least one (1) Business Day prior to the Closing Date, (i) ceased contributions to, and adopted written resolutions (or taken other necessary and appropriate action(s)) to terminate any Parent Employee Plan that is intended to qualify under Section 401(a) of the Code with a cash or deferred arrangement described in Section 401(k) of the Code (collectively, the “401(k) Plans”) in compliance with such 401(k) Plan’s terms and the requirements of applicable Law, (ii) made all employee and employer contributions to the 401(k) Plans for all periods of service prior to the Closing Date, including such contributions that would have been made on behalf of 401(k) Plan participants had the Merger not occurred (regardless of any service or end-of-year employment requirements) but prorated for the portion of the plan year that ends on the Closing Date, and (iii) 100% vested all participants under the 401(k) Plans, with such termination, contributions and vesting effective no later than one (1) day prior to the Closing Date. Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3) Business Days before their adoption or approval for the Company’s reasonable review and comment.

(d)            Parent Options. As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive, immediately prior to the First Effective Time a number of shares of Parent Common Stock equal to the number of shares underlying such Parent Option. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.

(e)            Parent Restricted Stock Units. As of immediately prior to the First Effective Time, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (i) the vesting of each outstanding and unvested Parent Restricted Stock Unit shall be accelerated in full effective as of immediately prior to the First Effective Time, contingent on the occurrence of the Closing and (ii) for each outstanding and unsettled Parent Restricted Stock Unit (including any Parent Restricted Stock Units accelerated under Section ‎6.6(e)(i) above) the holder thereof shall be entitled to receive, immediately prior to the First Effective Time a number of shares of Parent Common Stock equal to the number of vested and unsettled shares underlying such Parent Restricted Stock Units. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.

6.7            Indemnification of Officers and Directors.

(a)            From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the “D&O Indemnified Parties”), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys’ fees and disbursements (collectively, “Costs”), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&O Indemnified Party of a request therefor; provided that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&O Indemnified Parties’ rights with regards to counsel, following the First Effective Time, the D&O Indemnified Parties shall be entitled to continue to retain Sidley Austin LLP or such other counsel selected by the D&O Indemnified Parties.

(b)            The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.

(c)            From and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company’s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent’s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.

(d)            From and after the First Effective Time, Parent shall maintain directors’ and officers’ liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6) year prepaid “D&O tail policy” for the non-cancelable extension of the directors’ and officers’ liability coverage of Parent’s existing directors’ and officers’ insurance policies for a claims reporting or discovery period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent’s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such “D&O Tail policy” annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent’s current policies of directors’ and officers’ liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such “D&O tail policy” would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such “D&O tail policy.”

(e)            From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys’ fees, that are incurred by the persons referred to in this Section ‎6.7 in connection with their enforcement of the rights provided to such persons in this Section ‎6.7.

(f)            The provisions of this Section ‎6.7 are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&O Indemnified Parties, their heirs and their Representatives.

(g)            In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this Section ‎6.7. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this Section ‎6.7.

6.8            Disclosure. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent’s Form 8-K announcing the execution and delivery of this Agreement. Without limiting any Party’s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; provided, however, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this Section ‎6.8. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to Section ‎6.2(d) or pursuant to Section ‎6.3(e).

6.9            Listing. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent’s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule 5110, assist the Company in preparing and filing an initial listing application for the Parent Capital Stock on Nasdaq (including any Parent Common Stock issuable upon conversion thereof) (the “Nasdaq Listing Application”) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection with any action contemplated by this Section ‎6.9. All Nasdaq fees associated with any action contemplated by this Section ‎6.9, including any fees related to the engagement of a consultant (the “Nasdaq Fees”), shall be paid by the Company.

6.10            Tax Matters.

(a)            The Parties shall use reasonable efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section 1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section 1.368-3.

(b)            Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.

(c)            If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Proxy Statement, (i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Sidley Austin LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Sidley Austin LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the “Tax Certificates”). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.

(d)            Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.

6.11            Legends. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered “affiliates” of Parent for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.

6.12            Officers and Directors. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on Section ‎6.12 of the Parent Disclosure Letter are elected or appointed, as applicable, to the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on Section ‎6.12 of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on Section ‎6.12 of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.

6.13            Termination of Certain Agreements and Rights. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.

6.14            Section 16 Matters. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.

6.15            Allocation Information. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a) each holder of Company Capital Stock, (b) such holder’s name and address, (c) the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the “Allocation Certificate”).

6.16            Parent SEC Documents. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (“SEC Documents”). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

6.17            Notice of Certain Transactions. As reasonably practicable following the closing of any Interim Financing or Company Acquisition, the Company shall provide notice to Parent (email being sufficient) setting forth in reasonable detail the terms of such Interim Financing or Company Acquisition, including (i) in the case of any Interim Financing, the amount of proceeds actually received by the Company in connection with such Interim Financing and (ii) in the case of any Company Acquisition, the Fair Market Value associated therewith.

6.18            Obligations of Merger Subs. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.

6.19            Parent Financing. To the extent requested by the Company prior to the Closing, Parent shall use reasonable best efforts to amend, restate and/or supersede the Subscription Agreement, in the manner determined by the Company at the Company’s cost and expense, to allow for the purchase of additional shares (up to $200,000,000 of such additional shares at a price per share no less than the Nasdaq official closing price (as reflected on Nasdaq.com) immediately preceding the signing of such amendment or restatement of the Subscription Agreement or other or superseding subscription agreement) of Parent Common Stock (whether in a second tranche or otherwise) by new or existing investors.

Section 7. Conditions Precedent to Obligations of Each Party.

The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:

7.1            Regulatory Approvals. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.

7.2            No Restraints. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion thereof) shall have been complied with and no Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.

7.3            Stockholder Approval. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company Stockholder Vote.

7.4            Listing. The Nasdaq Listing Application shall have been approved by Nasdaq.

7.5            Lock-Up Agreements. The Lock-Up Agreements shall be in full force and effect.

7.6            Parent Charter Amendment. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing at least such amendments as are necessary to consummate the transactions contemplated by this Agreement.

7.7            Certificate of Designation. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.

Section 8. Additional Conditions Precedent to Obligations of Parent and Merger Subs.

The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:

8.1            Accuracy of Representations. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).

8.2            Performance of Covenants. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.

8.3            Documents. Parent shall have received the following documents, each of which shall be in full force and effect:

(a)            a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in Sections ‎8.1, ‎8.2, ‎8.4, ‎8.5 and ‎8.6 have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with Section ‎6.15 is true and accurate in all respects as of the Closing Date;

(b)            a certificate pursuant to Treasury Regulations Sections 1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section 1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;

(c)            the Company Valuation Schedule; and

(d)            the Allocation Certificate.

8.4            No Company Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.

8.5            Company Stockholder Written Consent. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.

8.6            Parent Financing. The Subscription Agreement shall be in full force and effect and proceeds of not less than the Minimum Concurrent Investment Amount shall have been received by Parent or will be received by Parent substantially concurrently with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.

Section 9. Additional Conditions Precedent to Obligation of the Company.

The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:

9.1            Accuracy of Representations. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).

9.2            Performance of Covenants. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.

9.3            Documents. The Company shall have received the following documents, each of which shall be in full force and effect:

(a)            a certificate executed by an executive officer of Parent certifying that the conditions set forth in Sections ‎9.1, ‎9.2 and ‎9.4 have been duly satisfied;

(b)            written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to Section ‎6.12 hereof; and

(c)            the Parent Net Cash Schedule.

9.4            No Parent Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.

Section 10. Termination.

10.1          Termination. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company’s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent’s stockholders, unless otherwise specified below):

(a)            by mutual written consent of Parent and the Company;

(b)            by either Parent or the Company if the Merger shall not have been consummated by September 30, 2025 (subject to possible extension as provided in this Section ‎10.1(b), the “End Date”); provided, however, that the right to terminate this Agreement under this Section ‎10.1(b) shall not be available to the Company or Parent if such Party’s (or in the case of Parent, Merger Subs’) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;

(c)            by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;

(d)            by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the date hereof; provided, however, that once the Required Company Stockholder Vote has been obtained (whether timely or not), Parent may not terminate this Agreement pursuant to this Section ‎10.1(d);

(e)            by either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent’s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii) the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; provided, however, that the right to terminate this Agreement under this Section ‎10.1(e) shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;

(f)            by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;

(g)            by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;

(h)            by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in Section ‎9.1 or Section ‎9.2 would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided further, that if such inaccuracy in Parent’s or Merger Subs’ representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this Section ‎10.1(h) as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this Section ‎10.1(h) and (ii) Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this Section ‎10.1(h) (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this Section ‎10.1(h) as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);

(i)            by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in Section ‎8.1 or Section ‎8.2 would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; provided that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; provided, further, that if such inaccuracy in the Company’s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this Section ‎10.1(i) as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this Section ‎10.1(i) and (ii) the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this Section ‎10.1(i) (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this Section ‎10.1(i) as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or

(j)            by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this Section ‎10.1(j), upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; provided, however, that Parent shall not enter into any Permitted Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under Section ‎5.4 and Section ‎6.3, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with Section ‎10.3(d).

The Party desiring to terminate this Agreement pursuant to this Section ‎Section 10 (other than pursuant to Section ‎10.1(a)) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.

10.2          Effect of Termination. In the event of the termination of this Agreement as provided in Section ‎Section 10, this Agreement shall be of no further force or effect; provided, however, that (a) this Section ‎10.2, Section ‎10.3 and Error! Reference source not found.11 (other than Section ‎11.8) and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of Section ‎10.3 shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.

10.3          Expenses; Termination Fees.

(a)            Except as set forth in this Section ‎10.3 and Section ‎6.9, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.

(b)            If (i) this Agreement is terminated by Parent or the Company pursuant to Section ‎10.1(e) or by the Company pursuant to Section ‎10.1(f), (ii) at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, a bona fide third party Acquisition Proposal for a change of control transaction with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii) within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction (excluding in each case any transactions occurring in connection with the liquidation, dissolution and winding up of Parent), then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $320,000 (the “Company Termination Fee”).

(c)            If this Agreement is terminated by the Company (other than pursuant to Section 10.1(e) or Section 10.1(f)), the Company shall pay to Parent, within ten (10) Business Days of such termination, a non-refundable fee in an amount equal to $500,000 for each month (or portion thereof) that has elapsed after May 30, 2025 at the time of such payment; provided that in no event shall the amount of the fee payable by the Company pursuant to this Section 10.3(c) exceed $2,000,000.

(d)            If this Agreement is terminated by Parent pursuant to Section ‎10.1(d), the Company shall pay to Parent, within ten (10) Business Days of such termination, a nonrefundable fee in an amount equal to $2,000,000. If (i) this Agreement is terminated by Parent pursuant to Section ‎10.1(g), (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, a, Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii) within twelve (12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $2,000,000.

(e)            If either Party fails to pay when due any amount payable by it under this Section ‎10.3, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this Section ‎10.3 and (ii) such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the “prime rate” (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.

(f)            The Parties agree that, subject to Section ‎10.2, the payment of the fees and expenses set forth in this Section ‎10.3 shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this Section ‎10.3, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this Section ‎10.3 on more than one occasion. Subject to Section ‎10.2, following the payment of the fees and expenses set forth in this Section ‎10.3 by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this Section ‎10.3 are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z) any amount payable pursuant to this Section ‎10.3 is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this Section ‎10.3(f) shall limit the rights of the Parties under Section ‎11.10.

Section 11. Miscellaneous Provisions.

11.1          Non-Survival of Representations and Warranties. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this Section 11 shall survive the First Effective Time.

11.2          Amendment. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company’s stockholders or before or after obtaining the Required Parent Stockholder Vote); provided, however, that after any such approval of this Agreement by a Party’s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.

11.3          Waiver.

(a)            Any provision hereof may be waived by the waiving Party solely on such Party’s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

(b)            No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

11.4          Entire Agreement; Counterparts; Exchanges by Electronic Transmission. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; provided, further, that only Exhibit D (including Exhibit A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section 251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

11.5          Applicable Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this Section ‎11.5, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with Section ‎11.7 of this Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.

11.6          Assignability. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; provided, however, that neither this Agreement nor any of a Party’s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party’s prior written consent shall be void and of no effect.

11.7          Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b) upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:

if to Parent or Merger Subs:

GlycoMimetics Inc.

9708 Medical Center Drive

Rockville, Maryland 20850

注意：Christian Dinneen-Long

電子郵件：cdinneen-long@glycomimetics.com

抄送（這不構成通知）：

Sidley Austin LLP

787 第七大道

紐約，NY 10019

注意：Asher m. Rubin; John Butler

電子郵件: arubin@sidley.com; john.butler@sidley.com

如果是公司：

新月生物製藥公司

221號新月街，23棟，105室

馬薩諸塞州沃爾瑟姆 02453

注意：喬納森·小提琴

電子郵件：jviolin@crescentbiopharma.com

抄送（這不構成通知）：

吉布森、鄧恩 & 克倫徹律師事務所

一號海濱中心，2600號套房
舊金山，加利福尼亞州94111
收件人：瑞安·穆爾，布蘭登·伯恩斯，克里斯·特雷斯特
電子郵件：rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com

11.8          合作. 各方同意充分配合另一方，並根據另一方的合理要求執行和提交進一步的文件、證明、協議 和文書，並採取其他措施，以證明或反映預想的交易，並實現本協議的意圖和目的。

11.9          可分割性. 本協議中任何條款或規定在任何情況下或任何司法管轄區內無效或不可強制執行，不應影響本協議其餘條款和規定的有效性或可強制執行性，亦不影響在其他情況下或其他司法管轄區內該無效或不可強制執行的條款或規定的有效性或可強制執行性。如果有管轄權的法院的最終裁決聲明本協議的任何條款或規定無效或不可強制執行，雙方同意作出此類裁決的法院有權限制該條款或規定，刪除特定的詞語或短語，或用一個有效且可強制執行的條款或規定替換該條款或規定，該條款或規定儘可能接近表達無效或不可強制執行的條款或規定的意圖，因此本協議應按修改後的版本有效且可強制執行。如果該法院未行使前面句子中授予的權力，雙方同意用一個有效且可強制執行的條款或規定替換無效或不可強制執行的條款或規定，以實現該無效或不可強制執行的條款或規定在經濟、業務和其他方面的目的，儘可能達到。

11.10        Other Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.

11.11        No Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&O Indemnified Parties to the extent of their respective rights pursuant to Section ‎6.7) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

[Remainder of page intentionally left blank]

In Witness Whereof, the Parties have caused this Agreement to be executed as of the date first above written.

In Witness Whereof, the Parties have caused this Agreement to be executed as of the date first above written.